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Urokinase Plasminogen Activator Receptor (uPAR) 
The urokinase receptor was originally identified as the receptor for the serine protease urokinase 
(uPA), involved in the plasminogen activation cascade and the regulation of metalloproteinases-
dependent proteolysis. It is a very peculiar molecule since it has no intracellular domain thus 
exerts its signalling through lateral interactions with other plasma membrane components. For 
this reason, uPAR could be defined “a very sociable molecule” and its interactome is so large that 
more than 42 proteins can directly interact with uPAR. Moreover, it is important to remark that 
uPAR can interact with members of three major families of membrane receptor i.e. G protein-
coupled receptors, receptor tyrosine kinases, and integrins [1]. uPAR belongs to an exclusive class 
of proteins equipped with a glycosylphosphatidylinositol (GPI) anchor that influences both the 
subcellular localization and obviously, the function of many membrane proteins such as enzymes, 
adhesion molecules, surface antigens and receptors. Through this ability, it plays a central role in 
progression, metastasis, angiogenesis and stemness of numerous solid tumors [2-7]. 
Figure 1 – uPAR domains and globular-like structure 
The urokinase receptor binds uPA. uPAR lacks a cytosolic domain but is composed by a GPI-anchor and three protein 
domains. [7] 
 
By binding uPA at the leading edge of the migrating cell, uPAR organizes a cascade of extracellular 
proteases that facilitate cellular penetration in tissues [8] and it also laterally associates with 
integrins in the plasma membrane, regulating the state of integrin activation [9]. GPI anchoring is 
a ubiquitous process, taking place in the endoplasmic reticulum. Such a link, between the 
functional protein and the plasma membrane, shows variations on a common theme, which 
consists of a phosphoethanolamine linker, a glycan core, and a phospholipid tail [10]. This lipid 
anchor determines uPAR localization and distribution on the plasma membrane, it confers high 
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mobility to move on the membrane and facilitates the redistribution of uPAR in lipid rafts and 
caveolae [11]. Besides the GPI-anchor, uPAR is composed by three protein domains, each one 
forming a globular-like structure (Figure 1). The GPI moiety is added post-translationally at the C-
terminus of domain III while there are two linker regions located between domain I and II and 
domain II and III. So formed, uPAR has a large external surface, particularly suitable for lateral 
interactions [12-15]. Together with its ligand uPA and the specific inhibitor Plasminogen Activator 
Inhibitor-1 (PAI-1), uPAR forms the so-called membrane-bound Plasminogen Activation System 
(PAS). After about 30 years of intensive research, PAS overexpression has reached the level of 
evidence 1 as an indicator of poor prognosis in node-negative breast cancer [16;17], and a pro-
tumoral role has been shown in all the malignancies where uPAR is over-expressed [18], thus 
eliciting clinical interest for its control in human cancers [19]. As a tumor promoting machinery, 
the PAS acts at two distinct levels: a) by regulation of cell invasion and motility [20], and b) by 
orchestrating receptor tyrosine kinases (RTK) signalling that results into cell proliferation and 
survival [7;21] (Figure 2). 
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Figure 2 – The Plasminogen Activation System 
uPAR binds the protease urokinase-type plasminogen activator uPA in its active and zymogen (pro-uPA) forms. uPA 
cleaves plasminogen, generating the active protease plasmin. Plasmin can reciprocally activate pro-uPA. Increased cell 
surface concentration of uPA or pro-uPA (by binding to uPAR) and plasmin or plasminogen (via multiple receptors) 
accelerates their mutual activation. Plasmin cleaves and activates matrix metalloproteases (MMPs). Both plasmin and 
MMPs degrade many extracellular matrix (ECM) components and activate growth factors or liberate them from ECM 
sequestration. The proteolytic activities of uPA and plasmin are antagonized by the serine protease inhibitors (serpins) 
plasminogen activator inhibitor 1 (PAI1; also known as SERPINE1) and PAI2 (also known as SERPINB2) and α2-
antiplasmin. uPA–uPAR binding promotes clustering of uPAR in the plasma membrane, possibly in cholesterol- and 
sphingolipid-enriched domains referred to as 'lipid rafts', and increases its ability to bind the ECM protein vitronectin. 
uPA also cleaves uPAR in the linker between its first and second domains (D1 and D2), generating a soluble D1 
fragment and a membrane-associated D2–D3 fragment. uPAR cleavage abrogates uPA binding, thereby inactivating 
the function of uPAR in proteolysis, and also inactivates or modifies the signalling functions of uPAR. [22] 
 
uPA, the main uPAR ligand, is produced as a catalytically inactive precursor, pro-uPA. This single-
chain zymogen is activated into the two-chain form, by the cleavage from a variety of proteases. 
When activated, it can exert its major biologic function, that is, to convert plasminogen to the 
active plasmin. In a reciprocal fashion, plasmin activates the single-chain pro-uPA [2;3;22;23]. 
Although a secreted protease, uPA can be tethered to the cell surface through binding of its 
growth factor-like domain to uPAR [7;24]. Both pro-uPA and uPA bind uPAR with similar affinities; 
however, cell surface-bound uPA is significantly more potent in the catalytic conversion of 
plasminogen to plasmin [25]. Plasminogen can be localized to the cell surface as well by binding 
to several membrane proteins, including annexin II and Plg-RKT [26;27]. Once activated by uPA, 
plasmin has a broad substrate collection. Whereas the canonical function of active plasmin is fibrin 
clot lysis, it can also cleave several non-collagenous components of the extracellular matrix (ECM), 
such as fibronectin and laminin [28-30]. In addition, plasmin is involved in proteolytic activation 
of additional proteases, for example, matrix metalloprotease (MMP) zymogens, including pro-
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MMP-1 and pro-MMP-3. uPA physiological inhibitor is the serpine PAI-1. It is released in an active 
S or Stressed conformation, which then is rapidly inactivated through the transition into an R or 
Relaxed form. This change of conformation naturally occurs rapidly unless PAI-1 associates with 
Vitronectin, which can be considered a PAI-1 cofactor and another important uPAR ligand [1]. PAI-
1/uPA complex is formed with high affinity and leads to PAI-1 cleavage. As a uPAR ligand, this 
complex, is catalytically inactive and moreover it cannot initiate signalling nor promote cell 
migration. At last, PAI-1 is fundamental for uPAR internalization through direct interactions with 
the LDL receptor-related protein-1 (LRP-1) which is a scavenger receptor [33-35]. uPAR 
internalization inhibits cell migration and provokes cell detachment through the inactivation and 
internalization of the integrins interacting with uPAR. Another important factor in the PAS is the 
Vitronectin (VN), which exerts important physiological and pathological functions including cell 
adhesion, migration, proliferation, fibrinolysis, hemostasis, immune response, thrombosis, 
atherosclerosis, restenosis and cancer [106]. VN is an adhesive glycoprotein that acts by binding 
to αvβ3, αIIβ3, αvβ5, αvβ1, αvβ6 and αvβ8 integrins, which control intracellular signalling 
pathways, cytoskeleton organization and gene expression. VN is also an important uPAR ligand 
that act promoting uPAR redistribution on the cell surface influencing pericellular proteolysis and 
focal adhesions [37;38]. uPAR binding to VN induces the formation of uPAR dimers promoting cell 
anchorage, but prevents interaction with G protein-coupled receptors and so uPAR-dependent 
signalling [39-42]. VN has been described as single- and two-chain forms. The latter, as it happens 
for pro-uPA, is generated through proteolytic cleavage and the two chains are connected by a 
single disulphide bond. This structure imposes that PAI-1 binding to VN blocks uPAR, inhibiting 
uPAR-mediated cell anchorage and integrin-dependent cell migration and adhesion [41;43;44]. It 
is also present a collagen-binding and one heparin-binding site that is especially responsible for 
VN-protein interactions mediating the binding of proteins such as heparin, collagen, 
proteoglycans, osteonectin, tenascin, complement complexes, thrombin-serpin complexes, 
plasminogen, and finally VN itself. As a result, this site is responsible for the oligomerization of VN. 
Moreover, VN is the cofactor of PAI-1, stabilizing the S conformation of this serpin thereby 
preserving its biological activity. The other side of the coin is that PAI-1 affects the adhesion- and 
migration-promoting activities of VN, and conversely VN inhibits PAI-1-dependent signalling and 
cell migration by impeding PAI-1 binding to LRP-1 [45-47]. All these complex interactions illustrate 
the way by which not only uPAR but also the other components of the uPAR system work together 
to exert a myriad of cellular effects. 
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Lateral uPAR partners 
Most of the side interaction that uPAR has are with half of the members of the integrin family 
(that includes 24 membrane receptors) that consist of heterodimers of one α and one β subunit. 
Integrins exert a wide array of functions in embryonic development, tissue homeostasis, 
inflammation, cell differentiation, adhesion, migration, cell cycle progression, angiogenesis and 
tumor metastasis. Their interaction with uPAR let this one to join further indirect connections with 
the integrin interactome or adhesome [48]. Moreover, uPAR is also involved in cell-cell contacts 
through trans-interactions with integrins [49]. uPAR is a regulator of integrin activity acting on 
affinity and avidity, but the reverse relationship is also true [50]. In line with this observation, uPAR 
occupancy by uPA is required for the correct functioning of most integrins [51-55]. The importance 
of the influence of uPA on uPAR-integrin interaction may also reside in the fact that uPA is a ligand 
of integrins [56-62]. Indeed, uPA may thus promote uPAR-integrin interaction by bringing together 
these receptors. Moreover, anti-uPAR antibodies effectively blocks αvβ3 activity inhibiting VN-
induced cell migration [63]. uPAR also increases integrin-dependent adhesion and migration 
[25;27;29;44;45]. Therefore, the influence of uPAR on integrins is functional exerting a broad 
effect on the cellular localization of integrins [64-68]. Furthermore, it is important to remark in 
this relationship, that uPAR upregulation enhances integrin activation, while downregulating uPAR 
results in integrin deactivation [26;31;44;50;57;63-66].  
 
Figure 3 – The Integrin Family 
Representation of the integrin family. [71] 
 
Finally, integrin activity and number are regulated via the LRP-1-dependent internalization of 
uPAR. By binding to uPA, PAI-1 promotes the internalization of the LRP-1/PAI-
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1/uPA/uPAR/integrin complex that leads to concurrent deactivation and internalization of the 
integrins associated with uPAR [35]. This process is particularly relevant in the context of cell 
motility when cell is moving and require the disorganization of adhesion sites.  On the other hand, 
integrins regulate uPAR activity, distribution and expression. In addition, uPAR-integrin interaction 
and localization are governed by integrin ligands VN, Fibronectin and Laminin [69]. Interestingly, 
the complexity of the relationship between uPAR and integrins is reinforced by the property of 
uPAR to transduce signals leading to activation of integrins; uPAR is used by many integrins as 
transducer for other integrins activation, showing that uPAR could regulate their activity serving 
as a membrane messenger [70]. Other important partners interacting with uPAR on the plasma 
membrane are many growth factor receptors or receptor tyrosine kinase (RTK) family. These are 
a very large family of 58 membrane receptors, which share a common structure: an extracellular 
domain where the ligand binds, a single transmembrane domain, and an intracellular domain that 
harbors the tyrosine kinase activity and the sites of phosphorylation. The mechanism of RTK 
activation is also similar. The binding of ligand induces in most cases the dimerization of the RTK 
and the autophosphorylation of its cytoplasmic domain that initiates the downstream signalling 
cascade. Several RTKs interact with uPAR: EGFR, PDGFR-β, and most likely IGF-1R and c-Met, which 
serve as membrane transducers mediating uPAR-induced signal to the cell [72-76]. The 
relationship between uPAR and EGFR is the most studied [72-77]. EGFR, integrins and uPAR 
together with other membrane and cytoplasmic components constitutes a large membrane 
signalling complex implicated in the regulation of downstream signalling such as the MAP kinase 
pathway, and the stimulation of cell growth and other cellular effects [72;77-85]. Direct 
interactions of uPAR with integrins and EGFR have been reported suggesting that uPAR may 
simultaneously bind to both integrin and EGFR. According to the present literature, uPAR-induced 
signal is mediated by the integrin that in turn transactivates EGFR showing that uPAR is using the 
integrin as membrane messenger [72;81]. Interestingly, both uPA and uPAR expression are 
EGF/EGFR-dependent [86-91] suggesting that this system is capable of auto-amplification: 
uPA/uPAR transactivate EGFR which then enhances uPA expression, in a continuous positive loop. 
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Figure 4 – The EGFR and the uPAR-mediated ERK cascade 
uPAR signals through α5β1 and α3β1 integrins in fibroblasts, kidney epithelial cell lines and some carcinoma cells. uPA 
binding to uPAR is required for signalling through β1 integrins. a) A physical association of uPAR and α5β1 integrin is 
implicated in fibronectin fibrillogenesis. Subsequent adhesion to insoluble fibronectin fibrils and the association of 
uPAR and α5β1 integrin with the epidermal growth factor receptor (EGFR) causes activation of focal adhesion kinase 
(FAK). This leads to downstream activation of Ras and the mitogen activated protein kinase (MAPK) extracellular 
signal-regulated kinase (ERK). b) uPAR–α3β1 integrin complexes are proposed to bind laminin and vitronectin. 
Signalling downstream of uPAR and α3β1 integrin is associated with the disruption of cell–cell junctions and the 
development of an epithelial–mesenchymal transition-like phenotype through Src activation. The Ras–MAPK kinase 
pathway is also activated by uPAR– α3β1 integrin signalling, and enhances pericellular proteolysis through the 
transcription of uPA. [21] 
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uPAR in Melanoma Progression 
Cutaneous melanoma, the deadliest of skin cancers, is caused by the transformation of 
melanocytes (pigment-producing cells) that accumulate genetic alterations, leading to abnormal 
proliferation and dissemination [92]. Melanomas remain a significant cause of mortality in 
Caucasians and tumors consist of heterogeneous populations whose biological properties still 
remain poorly characterized. Melanomas are believed to arise from a mature, differentiated 
melanocyte [93]. 
Figure 5 – Melanoma Evolution 
Briefly the evolution of melanoma, from the melanocyte to the transformation in the benign nevus until the 
development of a vertical growth melanoma. The last stage ends with the formation of distant metastases. [92] 
 
Melanocytes transformations require many genetic and environmental factors that enable their 
escape from the regulation of keratinocytes; for instance, the loss of E-cadherin and gain of N-
cadherin is a fundamental step for escaping from keratinocytes and starting interactions with 
dermal stromal cells, such as fibroblasts and endothelial cells [93]. So transformed melanocytes 
proliferate and spread into a benign nevus, lesions that rarely progress to melanoma probably due 
to oncogene-induced cell senescence [94]. Aberrant growth and further alterations can lead to 
transform into dysplastic nevus, which can either stay latent or progress to a more malignant 
stage. The majority of these do not give rise to malignant disease but a subset will begin to spread. 
Melanoma growth is well distinguished in a first radial growth phase, when cells proliferate and 
spread laterally mostly within the epidermis, and the vertical-growth phase, invading derma and 
leading to melanoma cell intravasation in the circulatory or lymphatic system. The transition to 
the vertical stage is associated with the acquisition of metastatic potential as the cells have 
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penetrated the basement membrane and the increasing vascularization of these lesions means 
that the cells have an available route for distant spread [95]. While most of the genetic alterations 
associated with melanoma development result from sporadic somatic mutations, only 10% of 
melanomas are familiar, due to familiar germline mutations in genes involved in regulating cell 
cycle progression, like CDKN2A and CDK4, or pigmentation, such as melanocortin receptor MC1R 
[96]. 50-70% of melanomas carry mutation in BRAF [97], a member of Raf family of 
serine/threonine kinases, which are effectors of the small GTPase Ras in the ERK/MAPK pathway. 
It is activated by lots of membrane-bound receptors, like receptor tyrosine kinases and G-protein-
coupled receptors, and it is involved in cell growth, survival and differentiation [98]. uPAR, 
influencing their activity, can lead to ERK/MAPK activation as yet described above. Also gain-of-
function mutation in Ras family members have been reported in melanoma which generally lead 
to enhanced ERK-mediated proliferation; NRAS is mutated in 15-30% of the cases, HRAS activation 
has occasionally been detected in melanoma, while KRAS mutations have not been described in 
human melanocytic lesions [99]. Anyway, to date the most common mutation in melanoma is the 
substitution of a glutamic acid with a valine at position 600 (V600E) of BRAF, which accounts for 
90% of BRAF mutated melanomas [97]. Further BRAF mutation have been discovered in 
melanoma that either activate ERK signalling directly (e.g. G465A, T598, K600E, A727V) or 
indirectly, towards CRAF in a RAS-independent manner (e.g. G466E/V, G469E, G596R, D594G) 
[98;100;101]. Besides the constitutive ERK signalling, BRAFV600E also contributes to neo-
angiogenesis by stimulating autocrine VEGF, invasion by promoting the expression of fibronectin 
and the component β3 of its receptor αvβ3, by inducing MMP-1 and MMP-2 activity and IL-8 
secretion [95;102-104], in vitro extravasation, in vivo lung metastasis development [105] and last 
it is also involved in metastatic spread and distant organ colonization [106]. Many studies reported 
the presence of a particular subpopulation of cancer cells characterized by self-renewability and 
the capacity to initiate, replenish and expand human tumors. These cancer cells with stem cells 
features and defined as cancer stem cells (CSCs) or tumor-initiating cells have been isolated from 
different human solid tumors, including melanoma [107]. This discovery has allowed a better 
understanding of the biology and neoplastic transformation of normal melanocytes, and the 
possible mechanisms by which melanoma cells acquire tumorigenicity. Several potential bio-
markers of CSCs have been described as expressed by human solid tumors including melanoma 
[108] even if none has been shown to be truly CSC-specific [109-113]. Morover, it should be 
considered the possibility that different subpopulations of CSCs may exist within single tumors 
(intratumoral heterogeneity) including melanoma [114-116] and/or among different tumors 
(intertumoral heterogeneity). Nevertheless, tumour-initiating cells have been successfully 
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isolated using appropriate cell surface markers, including CD44, CD24, CD133, epithelial cell 
adhesion molecule (EPCAM) and ATP-binding cassette sub-family B member 1 and 5 (ABCB1-5) 
[113;117-122]. These tumour-initiating cells can produce phenocopies of the original primary 
tumours when transplanted into NOD–SCID mice [123]. 
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CRISPR/Cas9 genome editing system 
CRISPR (Clustered Regularly Interspace Short Palindromic Repeats) system is a prokaryotic 
adaptable immune mechanism used by many bacteria and archaea to protect themselves from 
foreign nucleic acids, such as viruses or plasmids [124-127]. The first CRISPR description was from 
Osaka University researcher Yoshizumi Ishino in 1987 [128], who accidentally cloned part of a 
CRISPR together with the iap gene, his target of interest. The organization of the repeats was 
uncommon because repeated sequences are typically arranged consecutively along DNA. The 
function of the interrupted clustered repeats was not known at the time [129]. Later on, in 1993 
researchers of Mycobacterium tuberculosis in the Netherlands published two articles about a 
repeat cluster in this bacterium that was named "direct repeat (DR)" region. These researchers 
recognized the diversity in the composition of repeat cluster spacers [130]. At the same time, the 
later called CRISPR was also observed in the archaeal organism Haloferax mediteranii and its 
function was studied by Francis Mojica at the University of Alicante, Spain [131]. However the real 
begin of CRISPR history, is in 1997 when Ruud Jansen at the University of Utrecht, recognized a 
similarity among the structure of the iap repeats of E. coli, the DR region of M. tuberculosis and 
the repeat cluster of H. mediteranii, defining these as members of the CRISPR family. From that 
time on numerous CRISPR's were recognized in the whole genomes of bacteria and archaea that 
were published, indicating that CRISPR is a universal feature of prokaryotes. A major addition to 
the understanding of CRISPR came with the observation that the repeat cluster was accompanied 
in the prokaryotic genomes by a set of homologous genes, the CRISPR associated or Cas genes. 
Four Cas genes (Cas 1 to 4) were recognized and the Cas proteins showed helicase and nuclease 
motifs, suggesting a role of these proteins in the dynamic structure of the CRISPR loci. For many 
years CRISPR remain a “mystery item” until 2005, when three independent research groups 
showed that some CRISPR spacers are derived from phage DNA and extrachromosomal DNA such 
as plasmids [132-134]. In effect, the spacers are fragments of DNA gathered from viruses that 
previously tried to attack the cell. The source of the spacers was a sign that the CRISPR/Cas system 
could have a role in adaptive immunity in bacteria. The first publication proposing a role of 
CRISPR/Cas in microbial immunity, by Mojica et al., already predicted a role for the RNA transcript 
of spacers on target recognition in a mechanism that could be analogous to the RNA interference 
system used by eukaryotic cells. Koonin et al. extended that hypothesis proposing mechanisms of 
action for the different CRISPR-Cas subtypes according to the predicted function of their proteins 
[135]. The first experimental evidence that CRISPR could be an adaptive immune system was in 
2007 but we had to wait till 2014 to see the first example of use as a tool for editing the genome, 
when Zhang et al. [129] manipulated the resistance of S. thermophilus to phage by adding and 
13 
 
deleting spacers whose sequence matched those found in the phages tested. In 2008, Brouns et 
al. identified a complex of Cas protein that in E. coli cut the CRISPR RNA within the repeats into 
spacer-containing RNA molecules [126], which remained bound to the protein complex. In the 
same year, Marraffini [137] showed that a CRISPR sequence of Staphylococcus epidermidis 
targeted DNA and not RNA to prevent conjugation. All these findings confirmed the proposed 
RNA-interference-like mechanism of CRISPR-Cas immunity. A 2010 study provided direct evidence 
that CRISPR-Cas cuts both strands of phage and plasmid DNA in S. thermophiles [124;138].  
 
CRISPR System 
The CRISPR system can be found on both chromosomal and plasmid DNA. Type II CRISPR 
incorporate sequences from invading DNA (often derived from nucleic acid of viruses and 
plasmids) between CRISPR repeat sequences. These regions that are complementary to the 
foreign DNA are called Protospacers. Transcript from part of these regions are processed into 
CRISPR RNAs (crRNAs) and hybridizes with a second RNA called transactivating CRISPR RNA 
(tracrRNA) [139]. All togheter this complex of crRNA and tracrRNA binds the nuclease Cas9. 
Protospacer-encoded portion of the crRNA directs Cas9 to cleave complementary target-DNA 
sequences, if they are adjacent to short sequences known as protospacer adjacent motifs (PAMs). 
Protospacer sequences incorporated into the CRISPR locus are not cleaved presumably because 
they are not next to a PAM sequence (Figure 6a). 
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Figure 6 - CRISPR-Cas platform. 
(a) Natural bacterial system is composed of incorporate foreign DNA sequences into CRISPR arrays, which then 
produce crRNAs bearing “protospacer” regions that are complementary to the foreign DNA site. crRNAs hybridize to 
tracrRNAs and this pair of RNAs can associate with the Cas9 nuclease. crRNA-tracrRNA:Cas9 complexes recognize and 
cleave foreign DNAs bearing the protospacer sequences. (b) The most used engineered CRISPR-Cas system utilizes a 
fusion between a crRNA and part of the tracrRNA sequence. This single gRNA complexes with Cas9 to mediate 
cleavage of target DNA sites that are complementary to the 5′ 20 nt of the gRNA and that lie next to a PAM sequence. 
(c) Example sequences of a crRNA-tracrRNA hybrid and a gRNA. [141] 
 
This prokaryotic system has been adapted to be used in vitro, merging the crRNA with a part of 
the tracrRNA in a hybrid called guide RNA (gRNA) (Figure 6b). So, in the simplest and most widely 
used form of this system only two components must be introduced into and expressed in cells to 
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perform genome editing: the Cas9 nuclease and the gRNA. Twenty nucleotides at the 5’ end of 
the gRNA (corresponding to the protospacer portion of the crRNA; Figure 6c) direct Cas9 to a 
specific target DNA site using standard RNA-DNA complementarity base-pairing rules. The site to 
be cleaved must lie immediately 5’ of a PAM sequence, although recognition at sites with alternate 
PAM sequences could be possible, albeit at less efficient rates [140;142;143]. Thus, with this 
system, Cas9 nuclease activity can be directed to any DNA sequence by altering the first 20 nt of 
the gRNA that correspond to the target DNA sequence. Thanks to these extreme variability, this 
platform also functions efficiently in a variety of cells and organisms, not only for genes in bacteria 
but also for cultured transformed human cancer cell lines and human pluripotent stem cells in 
culture [144-147], as well as in a whole organism such as the zebrafish [148]. Cas9-induced double 
strand breaks (DSBs) have been used to introduce NHEJ (Non Homologous End Join)-mediated 
indel mutations as well as to induce HDR (Homologous Directed Repair) with double-stranded 
plasmid DNA and single-stranded oligonucleotide acting as a donor template (Figure 7). Being able 
to introduce DSBs at multiple sites in parallel with Cas9 is a unique advantage of this RNA-guided 
genome editing platform relative to meganucleases, ZFNs or TALENs. Moreover, this platform is 
easier to be used than previous editing systems because is based on RNA-DNA complementarity 
base-pairing rules and not on recognition between proteins and DNA. 
 
 
Figure 7 – Recombination systems 
DSBs induced by Cas9 can be repaired in one of these two ways. In the error-prone NHEJ pathway, the ends of DSB are 
processed by endogenous DNA repair machinery and rejoined, which results in random indel mutations at the site of 
junction. Indel mutations occurring within the coding region of a gene can result in frameshifts and can cause the 
creation of a premature stop codon, resulting in gene knockout. Alternatively, a repair template in the form of a 
ssODN can be supplied to active the HDR pathway, which allows high fidelity and precise editing. [149] 
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Cas9 variants 
Cas9 is a bi-lobed architecture protein with the gRNA nestled between the alpha-helical lobe and 
the nuclease lobe. These two lobes are connected through a single bridge helix.  
 
Figure 8 – Cas9 Structure and Motifs 
Front and rear views of the Cas9–sgRNA–DNA complex. [152] 
 
There are two main domains located in the multi-domain nuclease lobe: the RuvC, that shares an 
RNase H fold structure with other nucleases in the retroviral integrase superfamily [150], which 
cleaves the non-target DNA strand, and the HNH nuclease domain, that has a ββα-metal fold that 
comprises the active site, which cleaves the target strand of DNA [151]. Cas9 in complex with the 
crRNA and the tracrRNA recognizes and degrades the target dsDNA [149]. The gRNA base paired 
with target ssDNA is anchored by Cas9 as a T-shaped architecture. The nuclease also consists of a 
recognition lobe (REC) that match the target sequence in the host DNA. Several Cas9 mutants 
including REC domain deletion and residues mutations in the bridge helix (BH) domain have been 
tested. REC and BH mutants show lower or none activity compared with wild type, which indicate 
these two domains are crucial for the gRNA recognition and stabilization of the whole complex 
(Figure 9e and f). Normally Cas9 performs a double strand break in the target DNA site, while 
introducing a D10A or H840A mutation into the RuvC- or HNH-like nuclease domains results in the 
generation of a single cut (Figure 9b and c) [135;152]. These mutants also known as Nickase have 
also been shown to be useful for genome editing. Nickases cut either the complementary or 
noncomplementary DNA target strands, respectively, in vitro [140;153;154]. The choosen DNA 
repair pathways, by which these various alterations are introduced, remain undefined; one 
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potential mechanism that has been postulated is that passage of a replication fork through a 
nuclease-induced nick site might result in a DNA DSB. 
 
Figure 9 – Cas9 Mutants 
(a) Cas9 wt nuclease creates double-strand breaks at DNA target sites. (b) Cas9 nickase created by mutation of the 
RuvC nuclease domain with a D10A mutation. This nickase cleaves only the DNA strand that is complementary to and 
recognized by the gRNA. (c) Cas9 nickase created by mutation of the HNH nuclease domain with a H840A mutation. 
This nickase cleaves only the DNA strand that does not interact with the gRNA. (d) Paired nickase strategy for 
improving Cas9 specificity. Two D10A Cas9 nickases are directed by a pair of appropriately oriented gRNAs. This leads 
to promote two single nicks that, if introduced simultaneously, simulate a DSB. (e) Catalytically inactive or 'dead' Cas9 
(dCas9) (e.g., with mutations in both the RuvC and HNH domains). This can be recruited by a gRNA without cleaving 
the target DNA site. (f) Catalytically inactive dCas9 can be fused to a heterologous effector domain. [141] 
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Off target effect risks and possible solutions 
Even if very efficient, this system is not completely immune to errors. Understanding the possible 
weak sides could be helpful in order to prevent all potential off-target effects. Recently, a number 
of studies have examined potential off-target sites that differ from one to six positions from the 
on-target site in human cells [143;149;155-157]. These reports have found cases of off-target 
mutations at sites that differ by as many as five positions within the protospacer region [156] and 
that have an alternative PAM sequence [158]. Interestingly, indel mutation frequencies at these 
off-target sites can be so high (>2–5%) that sometimes can be comparable to the on-target site 
mutation frequency [156;159;160] even if more sensitive deep sequencing assays have identified 
lower frequency off-target mutations [149;155;157]. To prevent these effects, it has been 
suggested that higher GC content at the RNA:DNA interface might potentially help to stabilize 
binding the hybridization, indeed high rates of mutagenesis have been observed for off-target 
sites with as little as 30% matched GC content [143;156]. A recent published paper reported that 
using whole-exome sequencing did not find evidence of Cas9-induced, off-target mutations in 
three modified human K562 cell line clones [147] even if the high false-negative rate associated 
with exome sequencing analysis, limits interpretation of these data. However, these results 
suggest that with careful target selection, it may be possible to isolate Cas9-edited cells with a 
good successful rate. Overall, the various published studies strongly suggest that off-target sites 
of RNA-guided Cas9 nucleases can be variable in frequency and challenging to predict. For any 
given target site, it is not currently possible to predict how many mismatches can be tolerated, 
nor do we fully understand why some sites are cleaved whereas other are not. We also do not 
know how genomic and/or epigenomic context might affect the frequency of cleavage. Although 
some initial evidence suggests that DNA methylation does not inhibit Cas9-based genome editing 
[157], it seems plausible and likely, that chromatin structure could play a role in off-target site 
accessibility. One potential strategy to reduce off-target mutations is to reduce the concentrations 
of gRNA and Cas9 expressed in human cells. Another one is to use a modified gRNA architectures 
with truncated 3′ ends (within the tracrRNA-derived sequence) or with two extra guanine 
nucleotides appended to the 5′ end (just before the complementarity region) which yields better 
on-target to off-target ratios but generally with lower efficiency on on-target genome editing 
[143;147]. Morover, studies using single gRNAs have reported substantially higher editing rates 
than those using dual gRNAs [144;145;148;161]. These findings suggest that the single gRNA 
system may be more active than the double gRNA system, presumably because two components 
can assemble more efficiently than three components. However the best approach for improving 
specificity involves the use of paired nickases in which adjacent off-set nicks are generated at the 
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target site using two gRNAs and Cas9 mutant (see above Figure 9d). In contrast to single Cas9 
nickases (Fig.9b and 9c) (which can at some sites more favorably induce HDR events relative to 
NHEJ indels), paired Cas9 nickases targeted to sites on opposite DNA strands separated by 4 to 
100 bp can efficiently introduce both indel mutations and, in case a single-stranded DNA 
oligonucleotide donor template is used can induce HDR events in mammalian cells [159;162;163]. 
Importantly, paired nickases can reduce Cas9-induced off-target effects of gRNAs in human cells; 
the addition of a second gRNA and substitution of Cas9 nickase for Cas9 nuclease can lead to lower 
levels of undesired mutations. However, the second gRNA can itself induce its own range of off-
target mutations in the genome as multiple studies have shown that single monomeric Cas9 
nickases can function on their own to induce indel mutations at certain genomic loci, perhaps 
because an individual nick might be converted to a DSB when a replication fork passes through 
the locus [164;165]. The existence of these off-target effects and our inability to identify these 
alterations on a genome-wide scale mean that researchers need to account for the potentially 
confounding effects of these undesired mutations. One strategy to rule out off-target mutations 
is the use of complementation, reintroducing a wild-type gene, which can be used to confirm the 
effects of knockout. Another possibility is to use gRNAs targeted to different sites. Presumably, 
each gRNA will be expected to have a different range of off-target effects and therefore if the 
same phenotype is observed with each of these different gRNAs it would seem unlikely that 
undesired mutations are the cause. 
 
CRISPR delivery possibilities 
There are several methods to delivery all the components of CRISPR system. In cultured 
mammalian cells, can be used electroporation, nucleofection and Lipofectamine-mediated 
transfection of nonreplicating plasmid DNA to transiently express Cas9 and gRNAs 
[144;145;156;161]. Lentiviral vectors have also been used to constitutively express Cas9 and/or 
gRNAs in cultured human and mouse cells [167-169]. RNAs and/or plasmid DNA transcribed in 
vitro have been injected directly into the embryos of zebrafish, fruit flies, mice, rats and into the 
gonads of adult roundworms [148;166;169-178]. In addition to animal models and cell lines, it has 
been successfully used in multiple plant species including wheat, rice, sorghum, tobacco and thale 
cress [173-183]. For most applications, transient expression of gRNAs and Cas9 is typically 
sufficient to induce efficient genome editing. Indeed, after expression and selection plasmid 
expressing CRISPR machinery is usually lost. Although constitutive expression of these 
components may potentially lead to higher on-target editing efficiencies, extended persistence in 
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the cell might also lead to increased frequencies of off-target mutations, a well-known 
phenomenon for the ZFNs technology [184]. 
 
Other uses and perspectives 
In addition to the use described above, CRISPR-Cas system has the potential to be used to regulate 
endogenous gene expression or to label specific chromosomal loci in living cells or organisms. 
Catalytically inactive or “dead” Cas9 (dCas9) (Figure 9e) can be recruited by gRNAs to specific 
target DNA sites [140;173]. Targeting of dCas9 to promoters was initially shown to repress gene 
expression in both Escherichia coli and human cells [186;187] (Figure 10a).  
Figure 10 – Applications 
gRNA-directed dCas9 can be fused to activation domains (a) to mediate upregulation of specific endogenous genes, 
heterologous effector domains (b) to alter histone modifications or DNA methylation, or fluorescent proteins (c) to 
enable imaging of specific genomic loci. [141] 
 
Interestingly, dCas9 repressed a bacterial promoter efficiently when recruited with gRNAs that 
interacted with either strand of sequences upstream of the promoter. However, when targeting 
sites downstream of the transcription start, only gRNAs that interacted with the non-template 
strand induced dCas9-mediated repression. dCas9 also provides a general platform for 
recruitment of heterologous effector domains (Figure 4f) to specific genomic loci. For example, 
dCas9 fused to a transcriptional activation domain or a transcriptional repression domain have 
been shown to regulate the expression of endogenous genes in human and mouse cells [187-191]. 
However, multiplex recruitment of dCas9-based activators using between 2 and 10 sgRNAs 
targeted to the same promoter can result in substantially higher levels of human gene activation 
and this capability of dCas9-based activators to function synergistically is consistent with previous 
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observations for TALE-based activators. It has also been demonstrated that an EGFP-dCas9 fusion 
can be used to visualize DNA loci harboring repetitive sequences (Figure 10b), such as telomeres, 
with a single gRNA or non-repetitive loci using 26 to 36 gRNAs covering a 5-kb region of DNA [192]. 
This imaging system provides a powerful tool for studying chromosome dynamics and structure. 
In future, it will be interesting to see whether dCas9 fusions to histone modifiers and proteins 
involved in altering DNA methylation, can also be used to perform targeted “epigenome editing” 
(Figure 10c). Methods for expanding the targeting range of RNA-guided Cas9 will be important for 
inducing precise HDR or NHEJ events as well as for implementing multiplex strategies, including 
paired nickases. As noted above, the targeting range for Cas9, paired Cas9 nickases and dCas9 
fusions is restricted mainly by the need for a PAM sequence matching the form NGG. Other 
gRNA:Cas9 platforms with different PAM sequences isolated from Streptococcus thermophilus, 
Neisseria meningitidis and Treponema denticola have also been characterized [145;193;194]. 
Morover it is necessary to improve the reliability of the system in order to reduce off-target 
effects. It is likely that further improvements will be needed, particularly for therapeutic 
applications. Examples of such improvements might involve using protein engineering to modify 
Cas9 and/or modifying the nucleotides used by the gRNA to mediate recognition of the target DNA 
site. Alternatively, the construction of inducible forms of Cas9 and/or gRNAs might provide a 
means to regulate the active concentration of these reagents in the cell and thereby improve the 
ratio of on- and off-target effects [141]. Methods for efficient delivery and expression of CRISPR-
Cas system components will undoubtedly need to be optimized for each particular cell-type or 
organism to be modified. Collectively, these advances will be important for research use and 
therapeutic applications. Lastly, strategies for shifting the balance away from NHEJ-mediated indel 
mutations and toward HDR-driven alterations remain a priority. Although high rates of HDR can 
be achieved with the CRISPR and single-stranded DNA oligonucleotides, competing mutagenic 
NHEJ also occurs simultaneously. One of the drawbacks to developing an approach to improve the 
HDR:NHEJ ratio is that inhibition of NHEJ is likely to be poorly tolerated by most cells, given its 
central role in normal DNA repair. For therapeutic applications seeking to exploit HDR, reduction 
or elimination of competing NHEJ will be crucially important. The simplicity, high efficiency and 
broad applicability of the RNA-guided Cas9 system have positioned this technology to transform 
biological and biomedical research. The ease with which researchers can now make changes in 
the sequence or expression of any gene means reverse genetics can be performed in virtually any 
organism or cell type of interest. Although the off-target effects of Cas9 remain to be defined on 
a genome-wide scale, much progress has already been made toward improving specificity, and 
further advances will undoubtedly come rapidly, given the intensity of research efforts in this area. 
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All of these recent advances—and those to come—in developing and optimizing Cas9-based 
systems for genome and epigenome editing should propel the technology toward therapeutic 
applications, opening the door to treating a wide variety of human diseases. 
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Aim of the Project 
Recurrence is the main cause of treatment failure after surgery and chemotherapy. In the last 
decades, many resources were spent in order to find a way to detect that small number of cancer 
cells that remain quiescent and after an unspecified time, they recur forming a new tumor, sharing 
many features with the past one. Indeed often chemotherapy, although effective, does not 
destroy all tumor cells leaving a pool of chemo-resistant cells that are commonly invisible to all 
the detection methods. This pool of cells is referred as Cancer Stem Cells (CSC) that may generate 
tumors through the stem cell processes of self-renewal and differentiation [196-198]. In tumors, 
they form a distinct population and can cause relapse and metastasis giving rise to new tumors. 
CSCs are the core contributors that affect therapy failure, regardless of whether these 
determinants are present within a transitory state or in well-defined CSC populations. Therefore, 
we need to develop specific therapies targeting CSCs in order to disrupt the pool of cells that 
sustain tumor growth and recurrence. In this study, we focused on the Urokinase Plasminogen 
Activating Receptor (uPAR), a well-known molecule that hide a new unexpected role in tumor 
recurrence. Its expression increases with disease progression, correlates with poor prognosis and 
therefore was considered a good target for anti-tumoral therapy [199]. These chemotherapies 
with the addition of anti-uPAR impairing agents are aimed to block its protease- and anchorage-
dependent property but also its function to activate the cellular signalling of some receptor such 
as EGFR, IGFR, PDGFR and integrins receptors [1]. As many studies demonstrated, even if these 
therapies are effective they also showed that they are not capable to eradicate all the tumor cells. 
We have shown that uPAR is strongly over-expressed in human melanoma cells and that its 
presence controls either the mesenchymal (protease-dependent) and the amoeboid (protease-
independent) type of cell invasion [200]. We have also cleaved uPAR expressed in human 
melanoma cells by the uPAR-degrading enzyme MMP12, properly engineered within shuttle 
Endothelial Progenitor Cells (EPCs). Once delivered within experimental human melanomas 
xenografted in nude mice, such EPC-MMP12 inhibited tumor growth, angiogenesis and lung 
metastases [201]. Further, we have observed that uPAR expression is proportional to the phase 
of tumor progression of melanoma cells and that the TGFβ of conditioned medium of 
mesenchymal stem cells (MSC) induces an epithelial-to-mesenchymal (EMT) profile in melanoma 
cells, characterized by uPAR and TGFβ/TGFβ-receptor upregulation: TGFβ gene silencing in MSCs 
downregulates uPAR expression and EMT in melanoma [202].  Therefore, we decided to 
investigate what happens to melanoma cells when uPAR is completely Knock-Out, through the 
recent and innovative technique called CRISPR. Mounting evidence suggests that cancer may arise 
from a transformed stem cell, which is able to self-renew, differentiate into diverse progenies, 
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and drive continuous growth [203]. Indeed many characteristics suggest the presence of stem-like 
cells in melanomas like their phenotypic heterogeneity both in vivo and in vitro [4], their ability to 
express developmental genes [204] and their capacity to differentiate into a wide range of cell 
lineages, including neural, mesenchymal, and endothelial cells [205;206]. Given that all, we 
speculated that destroying or inactivating all uPAR in melanoma cells can lead to slow their cell 
cycle, showing an acquired chemo-resistance and a quiescent status that can cause the loss of all 
the possibilities to strike the tumor with the conventional chemotherapies. 
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Materials and Methods 
 
Cell lines 
The melanoma cell line A375 (MITF wild type, BRAF V600E, NRAS wild type) was obtained from 
American Type Culture Collection (Manassas, VA) and grown in Dulbecco’s modified Eagle’s 
medium (DMEM) High Glucose with 10 % FBS (Euroclone, Milano, Italy).  
 
Transfection and Plasmid 
The plasmids for CRISPR-Cas9 were obtained from Santa Cruz Biotechnology (Santa Cruz, 
California). Plasmid were diluted into Plasmid Transfection Medium at optimized concentration 
and transfected using UltraCruz Transfection Reagent according to the manufacturer’s 
instructions. Medium was replace after 48h of incubation at 37°C in 5% CO2 humidified incubator 
and cells were selected using 1ug/mL puromycin (Sigma-Aldrich, Saint Louis, Missouri, USA). 
Limiting dilution was then performed in order to select indivudual clones that were characterized 
using WB, PCR, Flow Citometry and Immunecitochemistry. 
 
Western blot analysis 
Cell pellets obtained by centrifugation were incubated with RIPA lysis buffer (50 mM Tris (pH 7.4), 
150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 5 mMEDTA) and proteinase 
inhibitor cocktail (Roche, Mannheim, Germany) for 30 minutes on ice. Lysates were then 
centrifuged at 14,000 r.p.m. for 10 minutes. Aliquots of lysates (40 μg) of A375 and M6 cells were 
subjected to Western blotting. The primary antibodies were anti-uPAR R-3 (1:1000; mouse 
monoclonal antibody, MON-R3 (Life Technlogies, Monza, Italy), which recognizes full-length uPAR; 
anti-uPAR R-4 (1:1000; mouse monoclonal antibody, MON-R4(Life Technlogies, Monza, Italy), 
which recognizes both uPAR full-length and truncated form; anti-Cyclin A/D1/E(Santa Cruz, 
California); anti-α Tubulin (Sigma-Aldrich, Saint Louis, Missouri, USA); anti-LC3A/B (Cell signalling 
Technology, Danvers, MA, US); anti-GAPDH (mAbcam, Cambridge, UK); anti-PARP (Cell signalling 
Technology, Danvers, MA, US); anti-p53 (Santa Cruz, California); anti-γH2AX (Cell signalling 
Technology, Danvers, MA, US); anti-pmTOR (Cell signalling Technology, Danvers, MA, US); anti-
pAkt (Sigma-Aldrich, Saint Louis, Missouri, USA); anti-Akt (pan) (Cell signalling Technology, 
Danvers, MA, US); anti-pERK (Cell signalling Technology, Danvers, MA, US); anti-ERK (Cell signalling 
Technology, Danvers, MA, US). Membranes were incubated in a blocking solution consisting of 
phosphate-buffered saline (PBS)/Odyssey Blocking Buffer 1:1 (PBS/OBB) (Lycor Bioscience) for 
1 hour at room temperature. Membranes were then incubated overnight at 4 °C with the 
26 
 
appropriate antibody, washed four times with PBS-Tween 0.1% solution, and probed with the 
secondary IRDye antibodies according to the manufacturer’s instructions. The protein bands were 
analyzed by the Odyssey Infrared Imaging System (Lycor Bioscience) using software for protein 
quantification. 
 
RNA extraction, semiquantitative and quantitative PCR 
Total RNA was prepared using Tri Reagent (Sigma-Aldrich, Saint Louis, Missouri, USA), agarose gel 
checked for integrity, and reverse transcribed with cDNA sintesys kit (BioRad, Milano, Italy) 
according to manufacturer's instructions. Selected genes were evaluated by qualitative PCR using 
Blue Platinum PCR Super Mix (Life Technologies, Monza, Italy) or Real-Time PCR using 
SsoAdvanced Universal Green Mix (BioRad, Milano, Italy) with 7500 Fast Real Time PCR System 
(Applied Biosystems, Waltham, Massachusetts, USA). For Real Time PCR, fold change was 
determined by the comparative Ct method using β2-Microglobulin as the normalization gene. 
Amplification was performed with the default PCR setting: 40 cycles of 95°C for 10 seconds and of 
60°C for 30 seconds using SYBR Green–based detection. Primer sequences (IDT, TemaRicerca, 
Bologna, Italy) are reported below.  
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Table 1 - Primer List 
All the primers are suitable for Real-Time PCR except Cyclin E, GAPDH and uPAR (910bp). 
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Immunofluorescence analysis 
Cells were grown on glass coverslips, washed twice with 1 ml of PBS, fixed for 20 minutes in 3.7% 
paraformaldehyde in PBS and permeabilized with 0.1% Triton X-100 in PBS for 5 minutes. The cells 
were incubated in blocking buffer (3% BSA and 0.1% Triton X-100 in PBS) for 1 hour at room 
temperature and then stained with the appropriate antibody overnight at 4° C. Successively, the 
cells were incubated at room temperature for 1 hour with the specific secondary antibody. Nuclei 
were stained with DAPI dye (4',6-diamidino-2-phenylindole; Life Technologies). Then, the cells 
were dried, mounted onto glass slides, and examined with confocal microscopy using a Nikon 
Eclipse TE2000-U (Nikon, Tokyo, Japan). A single composite image was obtained by 
superimposition of 20 optical sections for each sample observed. The collected images were 
analyzed by ImageJ software (developed by Wayne Rasband, National Institutes of Health, 
Bethesda, MD; available at http://rsbweb.nih.gov/ij/index.html). To calculate the correct 
Fluorescence values we draw an outline around each cell and circularity, area, mean fluorescence 
were measured, along with several adjacent background readings. The Corrected Total Cellular 
Fluorescence (CTCF) = integrated density – (area of selected cell * mean fluorescence of 
background readings), was calculated. 
 
Flow cytometry analysis 
Melanoma cells were harvested with Accutase (Euroclone, Milano, Italy), washed once with cold 
PBS and then stained with fluorochrome-conjugated mAbs anti-CD44 (Immunotools GmbH, 
Germay), -CD87 (Life Technologies, Monza Italy), -CD133 (eBioscience), CD243 (eBioscience), 
ALDH1 (Abcam) for 1h on ice in dark. The externalization of phosphatidylserine was determined 
by flow cytometric analysis of cell staining using an Annexin V-FITC conjugate (Immunotools 
GmbH, Germay) and PI according to the manufacturer's protocol. After washing in PBS plus Bovine 
Serum albumin 0.5% (BSA), cells were analyzed by flow cytometry BD-FACS Canto with 
DivaSoftware (BD Biosciences).  
 
Cell cycle analysis 
Cell cycle distribution was analyzed by the DNA content using PI staining method. Cells, starved 
for 24 h, were harvested, washed 2 times in PBS by centrifugation and stained with a mixture of 
100 μg/mL propidium iodide (PI), 20 μg/mL RNase A, 1 mg/mL trisodium citrate and 0.3 % (v/v) 
Triton X-100 in dark at room temperature for 30 min. The stained cells were analyzed by flow 
cytometry (BD-FACS Canto) using red propidium-DNA fluorescence. 
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CFSE Proliferation assay 
Cells were harvested with Accutase (Euroclone, Milano, Italy), wash once with cold PBS and then 
incubated with CFSE (Life Technologies, Monza, Italy) for 20 min at 37°C protected from light. After 
washing with cold PBS, five times the original staining volume of culture medium was added to 
the cells and incubate for 5 minutes. This step removes any free dye remaining in the solution. 
Cells were pelleted by centrifugation and then plated again in three P100 plates. T0 were 
harvested after 4 hours to let the reagent undergo acetate hydrolysis while the other two were 
harvested after 24 and 48 hours. Cells were then fixed and analyzed by flow cytometry (BD-FACS 
Canto). 
 
Tumor Spheroid Formation 
Tumor cell monolayers were washed with PBS and then harvested using Trypsin, collected and 
centrifuged at 500 x g for 5 min. Supernatant was removed and resuspended cell pellet in 1mL 
complete growth medium. 500 cells/well were seeded dispensing 200 μL per well into a 96-well 
flat-bottomed plate precoated with 1.5% Agar. The plate was centrifuged at 500 x g for 5 min and 
then transfered to an incubator (37°C, 5% CO2, 95% humidity). Four days later tumor spheroids 
formation was visually confirmed and we proceeded with the 3D assays. 
 
Tumor Spheroid Growth Kinetics and Treatment with Drugs 
Spheroids were generated as described above. Growth kinetics and inhibition assays were 
performed as previously reported [207]. 
 
Spheroid-based Migration Assay 
Matrigel (BD Biosciences) was diluted to 125 µg/mL in serum-free medium using pre-cooled 
pipette tips and dispensed 50 µL per well into the inner 60 wells of a 96-well flat-bottomed plate 
and incubated for 2h at RT. Wells were washed twice with PBS and then were distributed 200 µL 
per well of medium supplemented with 2% FBS. The 4 days old spheroids were transferred into 
the migration plate into a final volume of 300 µL/well. Spheroids were allowed to adhere to the 
surface for 30-60min before imaging the t=0 time point. 
 
2D Invasion assay 
Invasion of A375 melanoma cells was determined in vitro on Matrigel-coated polycarbonate filters 
(8µm pore size, 6.5 mm diameter), 12.5 mgMatrigel/filter, mounted in Boyden’s chambers. 1 x 10⁴ 
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cells suspended in 200 µL of DMEM with 2% FBS as in the lower chamber. Cells were incubated 
for 6 hours at 37°C, 10% CO2 in air. After incubation, filters were removed and the non-invading 
cells on the upper surface were wiped-off mechanically with a cotton swab. Cells on the lower 
side of the filters were fixed overnight in ice-cold methanol, then stained using a Diff-Quick kit (BD 
Biosciences) and pictures of randomly chosen fields were taken. 
 
Lactate Assay 
Lactate was measured in cultured media with Lactate Assay kit (Vinci-Biochem, Florence, Italy) 
according to the manufacturer’s instruction. In brief, samples were prepared in 50 µl/well with 
Lactate Assay Buffer in a 96-well plate. 50 µl Reaction Mix containing 46 µl Lactate assay buffer, 2 
µl Probe, 2 µl Enzyme Mix were added to each well and the reaction was incubated for 30 minutes 
at room temperature, protected fromlight. Lactate reacts with enzyme mix to generate a product, 
which interacts with probe to produce fluorescence. 
 
2-NBDG Uptake Assay 
Cells were incubated with 10 µM 2-NBDG (Life Technologies, Monza, Italy) for 60 min at 37°C, then 
harvested with Accutase (Euroclone, Milano, Italy) and washed with cold PBS. NBD fluorescence 
typically displays excitation/emission maxima of ~465/540 nm and can be visualized using optical 
filters designed for fluorescein. So cells were immediately analyzed by flow cytometry (BD-FACS 
Canto). 
 
Radiation Treatment 
Cells were irradiated with UVc at a dose of 60 J/m2 (254 nm; UV Stratalinker 1800, Stratagene). 
Damaging agent was applied at doses experimentally established to induce apoptosis rather than 
necrosis. The treatments proceeded for 24 h. 
 
Statistics 
Results are expressed as means ± SD. Multiple comparisons were performed by the Student test 
or One-way or Two-way ANOVA using GraphPad Prism 6. Statistical significances were accepted 
at * p<0.05. 
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Results 
 
Genomic engineering of melanoma cells using CRISPR-Cas9 
We transfected A375 melanoma cells with CRISPR-Cas9 D10A Mutant Plasmid in order to generate 
a complete PLAUR gene knock out. We then selected uPAR KO cells (thereafter called A375 PL1 
and A375 PL25) and evaluated the success of transfection with PCR, Western Blotting, Flow 
Cytometry and confocal analysis (Fig. 11a-d). We immediately noticed morphological changes, as 
they showed a round shape and bigger dimensions, respect to the cells transfected with CRISPR-
Cas9 Control Plasmid (A375 Control) (Figure 11e).  
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Figure 11 - Characterization of uPAR KO melanoma cells. 
(a) The expression of uPAR under confocal microscope. Cells were fixed and immunostained with uPAR MON-R4 in 
green. DAPI was used for nuclear staining. (b) Total RNA isolated using Trizol reagent was subjected to RT–PCR 
analysis and (c) immunoblot analysis was performed on total cell lysates, to determine the expression of uPAR in A375 
Control and uPAR KO CRISPRed cells. (d) Flow citometry analysis of uPAR. (e) Images of A375 Control and uPAR KO cells 
2 weeks after transfection. Cells were fixed and stained with Hematoxylin and Eosin. 
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Lack of uPAR causes growth inhibition 
A few days after uPAR KO, we observed a slower growth rate and, to assay that, we generated 
spheroids of A375 uPAR KO and A375 Control. These cells form particular spheroids commonly 
called “Loose Aggregate Spheroids” due to their melanocytic origin, as they grow as a compact 
mass at the center with friable aggregate cells all around like a sort of crown [17]. We monitored 
them for 14 days and we demonstrated that there is an evident growth inhibition in our uPAR KO 
cells (Figure 12a). We decided to repeat this also in a 2D assay simply counting plated cells at 24 
and 48 hours and the results were the same (Figure 12b). We further confirm these data by cell 
cycle analysis, observing a shorter S phase and an accumulation in G0/G1 and G2/M phases in 
uPAR KO cells, which is compatible with a cell cycle arrest (Figure 12c).  
 
Figure 12 - Lack of uPAR causes growth inhibition. 
(a) Agar-coated 96-well flat-bottomed plates were used to generate spheroids (a single spheroid per well). Starting 
from day 4 post generation, images were obtained at intervals using an inverted microscope. Analysis was carried out 
using ImageJ software and growth curves were obtained. Values are mean±SD (n = 20 spheroids/timepoint);(b)Cellular 
growth counting the total number of cell 24 and 48 h after the initiation of the culture; (c) DNA histograms were made 
by PI staining and FACS flow cytometry: the initial and last red peak represent G0-G1, G2-M stage respectively, middle 
is S stage. DNA histograms were analyzed by ModFitLT cell cycle analysis software. Percent cells in G2/M phase of the 
cell cycle are indicated in the table below; (d) Proliferation Index: fold expansion during culture (ratio of final cell count 
to starting cell count) as defined in ModFitLT. 
 
Treating cells with CFSE labelling dye, we were able to confirm previous results and assessed that 
lack of uPAR led to a slower cell cycle. As we can see in Figure 12d there were no evident changes 
after 24 hours, probably due to the latency phase of these cells, but after 48 hours we observed a 
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decreased proliferation index (the average number of divisions that all responding cells have 
undergone since the initiation of the culture) in the uPAR KO cells. This particular feature has been 
yet observed by Gopinath S. et al. [208] showing that uPAR is fundamental for tumor cell 
proliferation. By the way, uPAR plays also a major role on the plasma membrane physically 
engaging Vitronectin, EGFR, IGFR, PDGFR and integrins receptors regulating their functions. 
Indeed, a competent factor, such as the ones listed above, can initiate signalling events (i.e. 
extracellular signal-regulated kinase (ERK-1/-2) activation and c-myc induction) that is sufficient 
to drive cells out of G0 and lead them through the early portion of G1[209]. As we evaluated 
through PCR and flow cytometry, EGFR expression is strongly downregulated and is plausible that  
this loss leads the cells to remain in G0 (Figure 13).  
 
 
Figure 13 - Lack of uPAR causes growth inhibition. 
(a) EGFR mRNA expression was evaluated using total RNA isolated using Trizol reagent and then subjected to RT–PCR 
analysis and quantitative PCR. The results are means and SD (b) Flow citometry analysis of uPAR stained with FITC and 
EGFR stained with PE. 
 
As reported by Lui VW et al [210] the EGFR plays an important role in cell cycle. Indeed, the 
relationship between EGFR and the cell cycle has been primarily elucidated by examining the 
effects of specific EGFR-targeting agents on cancer cells. Attenuation of EGFR growth signalling by 
various therapeutic agents (i.e. EGFR antisense, monoclonal antibodies against EGFR, or specific 
tyrosine kinase inhibitors) results in cell cycle arrest in many tumor systems [211;212]. To better 
understand this phenomenon, we also evaluated Cyclins pattern through Western Blotting (Figure 
14a) and PCR (Figure 14b) and we assessed that, while there was not a noticeable change in 
Cyclines A and E protein expression, we observed a substantial upregulation of Cyclin D1 and a 
significant Cyclin A, B1, C, E and H downregulation in PCR. As demonstrated by Leslie K. Diaz et al. 
[213] Cyclin D1 has a role in the development of a metastatic phenotype, even if partly unclear, 
and is commonly correlated with poor prognosis. Cyclin C peaks in the G1 phase of the cell cycle 
and has been implicated both in G0 to G1 and G1 to S phase regulation [214;215]. It is particularly 
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important during the exit from G0 phase as it let the cells to stop resting and go in an active 
proliferation status. Cyclin H is closely related to EGFR as reported by Solmi R et al. [216] who 
reported that by treating cells with the EGFR inhibitor, Cetuximab, Cyclin H results downregulated. 
Cyclins E, A and B1 are involved in the transition from, in order, G1 to S, S to G2 and G2 to Mitosis. 
 
 
Figure 14 - Lack of uPAR causes growth inhibition. 
(a) Immunoblot analysis of total cell lysates, to determine the expression levels of Cyclins in A375 cells subjected to 
CRISPR KO. Expression levels of Cyclin A, D1 and E were checked by loading equal amounts of total protein. Tubulin was 
used as a loading control. Densitometry analysis was performed using ImageJ software; (b) Cyclins A, B1, C, D1, E and 
H mRNA expression was evaluated using total RNA isolated using Trizol reagent and then subjected to RT–PCR analysis 
and qualitative PCR. Densitometry analysis was performed using ImageJ software. 
 
 
 
 
 
 
36 
 
uPAR KO cells metabolic switch 
Apart the Cyclins pattern abnormalities and the loss of EGFR expression, we decided to investigate 
if a metabolic change can be responsible for the growth inhibition. Indeed, cell growth, especially 
for tumor cells, has a huge energetic requirement but when some metabolic disorder occurs, cells 
are forced to inhibit or arrest their growth. As we can see in figure 15a, after uPAR KO there is an 
evident downregulation of glucose, lactate and glutamine importers genes, GLUT1, GLUT3, MCT-
1 and ASCT2, which are responsible for the acquisition of the main metabolic sources for the ATP 
production. The upregulation of Pyruvate kinase isozymes M2 (PKM2) and Lactate Dehydrogenase 
A (LDHA) is commonly correlated with poor prognosis and with an advanced cancer progression 
[217]. Expression level of glucose-6-phosphatedehydrogenase (G6PD) is upregulated as well, 
indicating that there is also a greater use of the pentose phosphate way in order to get more 
NADPH to be used in many anabolic processes (an effect that is potentiated also by PKM2 
overexpression). We speculate that their increment, together with the transporters 
downregulation and the decreased oxidative phospotilation (OXPHOS) genes expression, could be 
due to a predominant glycolytic metabolism. The Lactate assay confirms that uPAR KO cells 
secrete more lactate in the medium than their uPAR positive counterpart (Figure 15b). Contrary 
to the downregulated expression of GLUT1 and 3, the Glucose Up-Take Assay (Figure 15c) 
demonstrated that uPAR negative cells are able to introduce glucose with the same efficiency as 
A375 Control cells. Indeed, even if glucose receptors are downregulated in uPAR KO cells, they 
have a very low Km (Michaelis-Menten constant), indicating that are capable to import glucose 
with a very high efficiency. The higher Glutaminases (GLS) expression in uPAR KO cells, which 
hydrolyze the amide group obtaining NH4+ and glutamate, that may fuel the intracellular pool of 
the Krebs cycle intermediates, could be due to the loss of the Amino-acid Transporter 2 (ASCT2). 
Indeed glutamine supply is a central factor for tumor cell proliferation, being a source of nitrogen 
for DNA and RNA synthesis. As reported by Bolzoni M et al. some types of human tumor cells 
exhibit a high requirement for glutamine (“glutamine addiction”) and use large amounts of the 
amino acid as an anaplerotic substrate [218]. However, all the other metabolic genes are 
downregulated meaning that there could be other ways which, with the tumor cells that lost uPAR 
expression, could feed themselves and could find the sources that they need to produce ATP. 
Therefore, we decided to investigate the autophagy process evaluating the expression of LC3 A/B 
protein isoforms. The cytosolic form of LC3 (LC3-I, 16 kDa) is conjugated to 
phosphatidylethanolamine to form LC3-phosphatidylethanolamine conjugate (LC3-II, 14 kDa), 
which is recruited to autophagosomal membranes. Autophagosomes fuse with lysosomes to form 
autolysosomes, and intra-autophagosomal components are degraded by lysosomal hydrolases 
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producing a moderate resource of ATP [219]. As assessed with the protein analysis (Figure 15d), 
there is a significant increase in LC3A/B isoform II which was sustained by co-treatment with 
Bafilomycin A, which is an inhibitor of the lysosomal proton pump and may also inhibit the fusion 
between autophagosomes and lysosomes preventing autophagic flux. To confirm this, we 
visualized LC3A/B using confocal microscopy (Figure 15e) and we confirm that, after 24 hours of 
starvation we could observe an increased level of LC3A/B in uPAR KO cells compared to control 
cells. 
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Figure 15 - uPAR KO cells metabolic switch. 
(a) Total RNA isolated using Trizol reagent was subjected to RT–PCR analysis and quantitative PCR was performed. The 
results are means and SD (b) Measurement of Lactate in medium conditioned for 24h; (c) The level of uptake of this 
glucose analogue after 1 hour incubation was determined by FACS as the geometric mean of fluorescence intensity of 
the cell population for each sample;(d) Immunoblot analysis of total cell lysates, of A375 uPAR KO cells with or without 
Bafilomycin, to determine the expression of LC3 in A375 cells subjected to CRISPR KO. Expression levels of LC3 A/B 
isoforms I and II were checked by loading equal amounts of total protein. Tubulin was used as a loading control. 
Densitometry analysis was performed using ImageJ software. (e) The expression of LC3A/B under confocal microscope. 
Cells were fixed and immunostained with LC3A/B in red. DAPI was used for nuclear staining. Densitometry analysis was 
performed using ImageJ software. 
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uPAR-mediated acquired chemoresistance 
These cells were also assayed for the capacity to resist chemotherapy. Indeed, chemotherapy is 
particularly effective on cells in a replicative status while, as seen above, uPAR KO cells are in a G0 
steady state. We tested two typical melanoma drugs, the Vemurafenib, which is a B-Raf enzyme 
inhibitor used on unresectable or metastatic melanoma bearing V600E mutation, and the 
Trametinib, which is MEK inhibitor that is commonly used on B-Raf V600E metastatic melanomas. 
As we can see in figure 16, uPAR KO cells are much more resistant to both drugs than A375 Control 
cells.  
 
Figure 16 - uPAR-mediated acquired chemoresistance. 
Day 4 A375 uPAR KO spheroids were treated with Vemurafenib (B-Raf enzyme inhibitor) or Trametinib (MEK1 and 
MEK2 inhibitor) with 1:2 serial dilutions (final concentrations 0 to 500 nM for Vemurafenib and 0 to 50 nM for 
Trametinib). Controls spheroids were treated with vehicle. Values are mean±SD (n=12) and a representative of three 
separate experiments for each agent is shown. 
 
This is only one mechanism used by multi drug resistance cancer cells to reduce sensitivity to 
anticancer drugs. Other mechanisms include an increase in drug efflux, the reduction of drug 
uptake, the activation of survival signalling, the dysregulation of DNA repair, and the inhibition of 
apoptosis signalling. To evaluate if other mechanisms are involved in the enhanced 
chemoresistance to these drugs we decided to observe the CD243 expression level. This cluster of 
differentiation is also known as ATP-Binding Cassette subfamily B member 1 (ABCB1) or Multi Drug 
Resistance Protein 1 (MDR-1) and is commonly linked to a stem-like phenotype and great 
metastatic potential [220;221]. As we can see in figure 17, ABCB1 is not expressed in A375 Control 
cells while there is an increased expression in uPAR KO cells demonstrating that this one could be 
one of the mechanisms, together with the slower rate proliferation, that led these cells to resist 
chemotherapies. In order to better understand these phenomena, we decided to evaluate the 
apoptosis resistance using UVc treatment, which is the gold standard to assay apoptosis in 
melanoma cells. 
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Figure 17 – ABCB1 expression uPAR-mediated. 
A375 uPAR KO cells were tested for CD243 (ABCB1; MDR-1) expression by FACS analysis; positive cells percentage are 
shown in the dot plots. 
 
 
uPAR KO melanoma cells are resistant to UV-induced apoptosis 
To induce apoptosis, we treated cells with UVc and after 24 hours, we evaluated the number of 
apoptotic and necrotic cells with Annexin V/PI staining. As we can see in figure 18a, A375 uPAR 
KO cells are more resistant than A375 Control, demonstrating that uPAR loss leads to a more 
apoptotic-resistant phenotype. This apoptotic insult led the cells to overexpress and activate p53 
machinery in order to repair the damaged DNA. In additon, PARP is more expressed in A375 
Control than in uPAR KO cells mediating a more resistant phenotype in the last (Figure 18b). 
Moreover, a part the total level of PARP in its uncleaved form, we can also see a minor activation 
in uPAR KO cells meaning that these cells are incapable of repairing and, in case of ATP-
deprivation, inducing apoptosis. The desensitization, of uPAR negative cells compared to A375 
Control, is also validated by the phosphorylation of H2AX that is phosphorylated on serine 139 
(called gamma-H2AX) as a reaction on DNA Double-strand breaks.  Indeed, uPAR KO cells have a 
minor activation of this UV-induced biomarker, meaning that after this kind of hurt, cells are less 
prone to find and repair the damage. By the way, as Malla et al. demonstrated few years ago, 
uPAR downregulation induces apoptosis through PI3K/Akt pathway [222]. In accordance, uPAR KO 
cells are composed from an evident part of cell population in early and late apoptosis. These could 
be due also to the propensity to use the autophagy pathway inducing, sooner or later, apoptosis. 
As we expected from previous studies, pAkt and pmTOR are downregulated in uPAR negative cells 
while pERK is strongly up-regulated (Figure 19). uPAR loss in fact, downregulating PI3K/Akt 
pathway, forces the cells to use ERK as an alternative pathway to grow and survive [223]. ERK up-
regulation could also be another responsible for the uPAR-induced chemoresistance, at least, to 
Vemurafenib and Trametinib. 
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Figure 18 - uPAR KO melanoma cells are resistant to UV-induced apoptosis 
(a) Annexin-V/PI FACS analysis of the three cell lines either untreated or treated with 60J/m2. (b) Immunoblot 
analysis of total cell lysates, of A375 uPAR KO cells treated with or without UVc, to determine the expression 
of PARP, pH2AX and p53. Expression levels were checked by loading equal amounts of total protein. Tubulin 
was used as a loading control. 
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Figure 19 – uPAR negative cells transduction pathway 
Immunoblot analysis of total cell lysates, of A375 uPAR KO cells, to determine the expression of pmTOR, pAkt and 
pERK. Expression levels were checked by loading equal amounts of total protein. Tubulin was used as a loading control. 
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uPAR deficiency leads to the acquisition of stem-like features 
The morphological changes, the slower growth rate, the glycolytic metabolic phenotype, the 
acquisition of the autophagic capacity, the chemoresistance and the apoptosis resistance are all 
typical features of cells who gained a stem-like phenotype [224]. Cancer Stem Cells (CSCs) often 
express distinctive markers like CD133, CD44, CD24, ABCB1/5, ALDH1 and many others, though 
many of them are tissue and tumor related. Even if a universal marker for CSC identification 
remains undiscovered, multiple malignancies have been shown to contain stem-cell like 
population capable of initiating tumors in xenograft model [225]. As shown in figure 20a, 
performing a cytometer analysis, we discovered that our uPAR negative cell lines express two stem 
cell markers otherwise not expressed in control A375, while there are no changes in CD44 
expression in both control and uPAR KO cells (data not shown). Moreover, as demonstrated 
above, also CD243 is expressed in these uPAR negative cells. To further analyze uPAR-mediated 
stem-like phenotype acquisition, we performed a Real-Time PCR for the Yamanka’s factors [226] 
and for Nanog, one of the gene that is involved in the maintenance of the stem state [227-230]. 
As we can see in figure 20b the expression of SOX2 and Oct3/4 is upregulated while KLF-4 and c-
myc are substantially not expressed. Regarding Nanog expression, we reported different levels in 
our two clones. 
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Figure 20 - uPAR deficiency leads to the acquisition of stem-like features. 
(a) A375 uPAR KO cells were tested for CD133 and ALDH1 expression by FACS analysis; positive cells percentage are 
shown in the dot plots. (b) Total RNA isolated using Trizol reagent was subjected to RT–PCR analysis and quantitative 
PCR was performed. The results are means and SD; P < 0.05 
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Discussion 
Overall, our study demonstrated the deep impact that loss of uPAR can have on human melanoma 
cells. uPAR is fundamental for their growth as for their invasive and migratory ability. As we 
previously demonstrated [200-202] uPAR mediates both the amoeboid movement, through Rho 
GTP-ases, and the mesenchymal movement through its action on the plasminogen system and the 
metallo-proteases (MMPs) cascade. Therefore, the inhibition or complete knock-out of uPAR gene 
leads to a great reduction in melanoma cell invasion and migration. Indeed, uPA/uPAR system is 
actually considered the main system involved in tumor invasion and metastasis, as well as in tumor 
angiogenesis [18]. Endogenous levels of uPA and uPAR increase with disease progression, 
correlate with poor prognosis and outcome in patients, and therefore uPAR can be considered a 
promising target for anti-tumoral therapy [199]. uPAR plays a major role in invasivity of malignant 
cells since it is involved both in ECM degradation and in cell adhesion through a “grip-and-go” 
mechanism [231]. It has been previously shown that uPA-uPAR interaction induces endothelial 
cell chemotaxis [232] and stimulates angiogenesis in the rabbit cornea [234]. Inhibition of uPAR 
expression blocks tumor cell invasion, angiogenesis and metastasis [200;234], and MMPs 
activation [235]. Also, uPAR induces EMT in cancer cells [236] and is involved in hypoxia-induced 
EMT [237]. Tumor progression is also characterized by increased expression of uPA/uPAR system, 
and many data indicate a regulative role of TGFβ on uPA/uPAR system in normal and cancer cells 
[238-240]. However, uPAR is transiently expressed whenever cell movement is required, as during 
inflammatory events, wound repair and tumorigenesis, while its expression is low in normal 
quiescent tissues. In the tumor microenvironment uPAR is expressed not only in tumor cells but 
also in endothelial cells, fibroblasts, inflammatory and mesenchymal stem cells [241;242]. We 
speculate that this opportunistic expression might be also used by tumor cells to shift from a 
proliferative and invasive phenotype to a quiescent steady state in order to escape chemo- and 
radiotherapy and finally generate new neoplastic lesions at local or distant sites. Indeed, when a 
sub-population of cancer cells within tumor mass become resistant to therapy, it can generate, 
after the clinical treatments, a new tumor causing recurrence. Presumably, these cancer cells are 
those that survive therapy and lead to relapse [225]. Even if every cell within the tumor mass 
possesses tumorigenic potential, the presence of a discrete subset responsible for treatment 
resistance would have an incontestable clinical significance. Cells who gained stem-like phenotype 
are commonly defined as Cancer Stem Cells (CSC) or Tumor Initiating Cells (TIC). The CSC concept 
potentially explains not only the low clonogenic capacity of most malignancies but also why 
treatment responses rarely translate into complete remission for cancer patients: initial responses 
in cancer represent therapeutic effectiveness against the bulk cancer cells, while rarer but more 
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resistant CSCs theoretically are responsible for the minimal residual disease (MRD) and tumor 
relapse. Considering that CSCs are more resistant to therapy than the bulk tumor cells and thus 
responsible for cancer relapse then, minimal residual disease after treatment should be enriched 
of these cells. Furthermore, the presence of CSCs after therapy should predict recurrence. Indeed, 
it has been recently found that residual breast tumor cell populations persisting after conventional 
treatment are enriched for phenotypic breast CSCs [243]. Similarly, patients with myelodysplastic 
syndrome continue to have a population of phenotypically distinct myelodysplastic stem cells 
(CD34+ CD38lowCD90+), even in complete clinical and cytogenetic remissions [244]. These cells 
appear resistant to lenalidomide, a Thalidomide derived, treatment and may account for disease 
relapse. It is very important to improve our understanding of the mechanisms through which MRD 
acts because it may lead to the way for better defining CSCs. While the identification and 
characterization of CSCs from hematologic malignancies was founded on decades of biologic 
experience in human hematopoiesis, limited understanding of the biology of their normal 
counterparts has disadvantaged the study of solid tumor CSCs. Thus, initial research of CSCs in 
solid tumors was based on findings in liquid malignancies. Accordingly, breast CSCs, initially 
described as CD44+ CD24low, were identified by their ability to generate tumors in 
immunodeficient mice [245]. This description was followed quickly by the discovery of CSCs 
expressing CD133 in brain cancers [113]. Since then, although the importance of any specific 
marker for CSC identification remains unclear, multiple malignancies have been shown to contain 
a stem-cell like population capable of initiating tumors in a xenograft model (Table 1). Back in 
1953, Nordling [246] was the first to formulate the theory that cancer results from an 
accumulation of DNA mutations. This was further refined by several researchers including Ashley 
[247], Knudson [248] and Nowell [249]. In this model of carcinogenesis, inherited mutations 
and/or environmental carcinogens lead to the development of premalignant clones. These cells 
further accumulate genetic hits until one single cell reaches a critical genetic or epigenetic state 
that confers a growth and/or survival advantage over the other normal cells. Over time, if it can 
evade the immune system, this abnormal cell would give rise to a malignant tumor. The cell that 
suffered the “critical insult” is the primordial cancer-initiating cell and the tumor, that will develop 
from that cell, will represent its clonal expansion. As postulated by Ashley, a cancer-initiating cell 
must survive long enough to accumulate three to seven genetic mutations necessary to generate 
cancer [247].  
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Table 2 – CSC Markers of Identification 
ABCB5, ATP-binding cassette subfamily B member 5; ALDH1, aldehyde dehydrogenases 1; CD, cluster of differentiation, 
Ep-CAM, epithelial cell adhesion molecule; ESA, epithelial specific antigen; IL2Rγ−/−, interleukin 2 receptor gamma 
knock out; Lin, lineage; NOD/SCID, nonobese diabetes/severe combined immunodeficiency; NMRI, Naval Medical 
Research Institute; nu/nu mice, homozygous nude mice. [226] 
 
Nowell [249] hypothesized that the inherent longevity and extensive proliferative capacity of a 
stem cell within a normal tissue make it the ideal candidate to be the cancer-initiating cell. On the 
other hand, most terminally differentiated cells are neither long-lived nor possess the ability to 
produce tumors with the limited number of divisions remaining in their differentiation program. 
The way through which a tumor generates from a single cell that suffered a series of insults would 
explain why only a minority of cells from most hematologic malignancies and solid tumors are 
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clonogenic in vitro and in vivo. In this CSC model, the cancer-initiating event, while conferring 
some advantages to the original cancer cell, does not completely alter its differentiation program; 
the malignant tumor would thus consist of a heterogeneous population of cells including the 
differentiated progeny of the original cell, simulating the hierarchical structure of the normal 
tissue of origin. Since the primordial cancer-initiating cell or one of its progeny in this model 
possesses self-renewal capability and at least some differentiation potential, this cell naturally 
came to be called a CSC. Alternatively, it is also conceptually possible that the low clonogenicity 
of cancer is the result of all cells within a cancer retaining the capacity to proliferate but only at a 
low rate. Which of these two scenarios account for the low clonogenicity of most cancers has been 
debated for years. As we demonstrated above, melanoma cells that through CRISPR/Cas9 
technique loss uPAR gene (PLAUR) undergo a series of alterations that confer them a stem-like 
phenotype. First of all, the growth inhibition, caused by cyclins pattern alteration and maybe by 
the metabolic dysregulation, is the main imprint of the cancer stem cells. uPAR itself, binding to 
uPA leads to the downstream activation of plasminogen and matrix metalloproteases, which lyse 
the extracellular matrix, releasing and activating matrix-bound growth factors which are 
important for supporting tumor growth [250;251]. As reported by Nathan Moore and Stephen 
Lyle [252], heterogeneous tumors are predicted to contain a population of slow cycling cells. 
Conventional radiotherapy or chemotherapies target and kill rapidly proliferating cells, while does 
not affect quiescent cells. Moreover, resistance to cytotoxic treatments may also be attributable 
to that lower proliferative rate [252;253]. CSCs from a variety of tumors have been shown to be 
slow cycling and to exhibit an increased level of quiescence compared to the majority populations 
of cancer cells within certain tumors [254;255]. CSCs that survive chemotherapy, after an 
unspecified period of time, re-enter the cell cycle and re-establish the tumor. Chemotherapy and 
radiotherapy have been considered treatments of choice for the past half-century, often affording 
remarkable reductions in tumor burden. However, induction of a stem-like phenotype leads to 
the acquisition of resistance to both radio- and chemotherapy, a phenomenon that has been 
extensively documented in breast and ovarian cancers [256;257]. Today, we possess only a partial 
and incomplete understanding of the actual biochemical and cell-physiologic mechanisms 
underlying the intrinsic chemo- and radio-resistance of tumor cells that became insensitive after 
the acquisition of the stem state. In addition, the resistance to chemotherapy in normal stem cells 
has been attributed to high-level expression of anti-apoptotic proteins [258] and to ABC 
transporters that are capable of efflux of the Hoechst dye, creating the so called “side population 
(SP)” observed upon fluorescence-activated cell sorting [259-261]. As we demonstrated, uPAR 
Knock Out leads to the acquisition of resistant phenotype to drugs such as Vemurafenib and 
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Trametinib, a biological phenomenon that we connect with the slower proliferation rate of uPAR 
knock out cells, but also with their expression of ABCB1 protein. In addition, another characteristic 
of uPAR knock out cells can account for such chemo-resistance: with respect to uPAR expressing 
cells, our KO clones are characterized by an increased activation of ERK1/2 pathway, at the 
expense of PI3K/Akt. Thereby, probably because of such increase, these cells can better survive 
to drugs that selectively affect ERK pathway, which is the case of Vemurafenib (anti-BRAFV600E) and 
Trametinib (anti-MEK) [243].  
Figure 21 – CSCs chemoresistance and recurrence 
Cancer stem cells (grey) self-renew and differentiate within tumours to form additional cancer stem cells as well as 
non-tumorigenic cancer cells (orange), which have limited proliferative potential. Therapies that kill, induce 
differentiation or prevent the metastasis of cancer stem cells represent potential cures. Therapies that kill primarily 
non-tumorigenic cancer cells can shrink tumours, but will not cure the patient because the cancer stem cells will 
regenerate the tumour. The intrinsic differences in tumorigenic potential among cancer cells might also explain why it 
is possible to detect disseminated solid cancer cells in patients that never develop metastatic disease. The 
identification and characterization of cancer stem cells should therefore also lead to diagnostic methods that can 
distinguish between disseminated tumorigenic and non-tumorigenic cells, as well as provide a better understanding of 
the mechanisms that regulate migration of cancer stem cells. [262] 
 
Moreover, uPAR KO cells are also characterized by an enhanced resistance to apoptosis induced 
by Ultraviolet (UV) rays. Cells hit by UV are subjected to the formation of double strand breaks in 
DNA and the phosphorylated form of histone H2AX allows the DNA to be repaired. We showed 
that, in uPAR KO cells, not only pH2AX is less activated but also PARP shows lower activity in 
response to this kind of insult. Interestingly, by analyzing PARP signal in either wild-type or uPAR 
KO cells, we observed that its total expression is less in cells without uPAR expression.  PARP is 
involved in DNA repair and in induction of programmed cell death. Thereby, its decreased 
expression could cause such increase in apoptotic threshold of uPAR KO cells. By the other hand, 
50 
 
we observed that A1 and A25 clones in standard condition are characterized by a basal apoptotic 
level, while uPAR expressing cells do not activate apoptotic program at all in normal condition. 
This is in accordance with the literature. Indeed, it has been demonstrated that downregulation 
of uPAR and cathepsin B decreased the Bcl-2/Bax ratio [222] and initiated partial extrinsic 
apoptotic cascade accompanied by the collapse of mitochondrial membrane potential in SNB19 
glioma cells [263]. Moreover, Kin et al. [264] reported that downregulation of uPAR was associated 
with increased expression of the pro-apoptotic protein Bax in glioma cells. Taken together, these 
results suggest that uPAR downregulation could induced apoptosis by modulating the Bcl-2/Bax 
ratio accompanied by collapse of mitochondrial membrane potential. We also investigated the 
impact that uPAR deletion had on cancer metabolism. It is well known that during the Warburg 
effect, cancer cells generate ATP through glycolysis rather than oxidative phosphorylation, even 
under non-hypoxic conditions [265]. To confirm this, a recent study reported a metabolic switch 
to glycolysis that occurs upon generation of breast CSCs [266], in accordance with another one 
showing that the components of the mevalonate metabolic pathway are important in the 
generation of breast CSCs. Indeed, the inhibition of this pathway by using hydroxy-3-
methylglutaryl CoA reductase blockers, resulted in loss of CSC specific properties [267]. These 
studies suggest that the alteration of the cell metabolism could be an essential step required for 
the entrance into the CSC state. In our study, despite we did not observe any significant variation 
in glucose uptake, in uPAR KO cells we noticed a strengthening in the glycolytic pathway at the 
expense of the oxidative-phosphorylation. In agreement with this, we observed an up-regulated 
expression of Lactate Dehydrogenase A (LDHA) and Monocarboxylate Transporter 1 (MCT-1). The 
first one catalyzes the inter-conversion of pyruvate and L-lactate with concomitant inter-
conversion of NADH and NAD+ while the second one exports lactate to the external 
microenvironment [268;269]. This is a typical metabolic adaptation in tumor cells discovered in 
the 1920s by Warburg who showed that glycolysis, which normally increases under anaerobic 
conditions, was often enhanced in cancers in the presence of abundant oxygen, the so called 
aerobicglycolysis or “Warburg effect” [265;270-271].  
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Figure 22 – The Warburg effect 
The aerobic glycolysis mechanism at the base of tumor proliferation. [271] 
 
This switch from oxidative phosphorylation to glycolysis, with its concomitant accumulation of 
lactate by-products in the tumor microenvironment, represents the best-known alteration of 
tumor cell metabolism [272]. It has been clearly proven that theconsequent increased acidification 
of the extracellular microenvironment drives tumor cell adaptive programs and may stimulates 
the evolution of the tumor niche [273-276]. Despite Glycolysis is a less efficient pathway to 
produce ATP, it is more rapid than mitochondrial oxidative phosphorylation. Another advantage 
of aerobic glycolysis for cancer cells is that generates less ROS than OxPhos metabolism, allowing 
cell adaptation to the intermittently hypoxic conditions prevalent in a poorly vascularized tumor. 
PKM2, which is up-regulated in uPAR KO cells, is commonly expressed in cancer cells and can be 
allosterically activated by fructose-1,6-bisphosphate [277-279] and drives the conversion of 
phosphoenolpyruvate to pyruvate, with concomitant phosphorylation of ADP to ATP. Cells can 
raise their intracellular NADPH by increasing flux through an alternative route of glucose 
metabolism called the pentose phosphate pathway (PPP), which is primarily anabolic, produces 
ribose sugars for nucleotide biosynthesis. In case of glycolytic precursors or intermediates 
accumulation, glucose-6-phosphate is oxidized by G6PD, catalyzing the generation of NADPH. The 
main substrate for the non-oxidative arm of the PPP is ribulose-5-phosphate, which can be 
generated either by the oxidative arm or by conversion from fructose-6-phosphate. Ribulose-5-
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phosphate is then processed to ribose sugars that feed into nucleotide biosynthesis. In addition, 
intermediates generate precursors for amino acids, lipids, and hexosamine sugars via a collection 
of secondary biosynthetic pathways that support anabolic growth. G6PD work at low basal rate in 
non-transformed cells and it becomes strongly upregulated during tumorigenesis [280]. As we 
demonstrated, G6PD is much more expressed in uPAR KO cells meaning that it could be involved 
in the defense against oxidative stress and it can confer to the cells the substrates they need to 
proliferate. Regarding the glutamine pathway, uPAR KO cells have an upregulated expression of 
glutaminases (GLS) indicating that these cells, accordingly to the Warburg effect, exploit this 
mechanism to survive, proliferate and defend themselves from the oxidative stress. Indeed, once 
uptaken, glutamine is rapidly metabolized by GLS in glutamate that can be used directly for the 
synthesis of reduced glutathione by the enzyme glutathione cysteine ligase, sustaining the 
antioxidant response [281]. Alternatively, glutamine can be deaminated to produce α-
ketoglutarate to fill levels of tricarboxylic acid cycle intermediates in a process named 
anapleurosis. Utilization of glutamine by transformed cells is commonly upregulated, consistent 
with the increased demand for energy, biosynthetic precursors, and redox substrates. The overall 
effect is the up-regulation of reduced glutathione synthesis to scavenge ROS, as well as the 
stimulation of the PPP to produce NADPH that can be used in turns to regenerate reduced 
glutathione. The Warburg effect is tremendously advantageous for the growth and the survival of 
many cancer cells. However, as we have demonstrated, when melanoma cells loss uPAR 
expression, while they acquire a glycolytic phenotype and stem features responsible for the 
acquisition of chemo-resistance and a higher apoptotic threshold, at the same time they become 
incapable to proliferate. This could be a two-edge sword because these cells, even if growing 
slowly, enrich the pool of CSCs causing in the long term the recurrence of the disease. As we know, 
in many solid tumors, there is an invasive front where the cells overexpress uPAR in order to 
transit from an epithelial phenotype to a mesenchymal one, to enhance their invasive and 
migratory ability and then intravasate into the bloodstream and metastasize in distant organs 
[282]. On the other hand, in the core of tumor mass there are cells expressing low levels of uPAR 
or even not expressing it at all. We speculate that these cells are able to regulate uPAR 
transcription in order to stop proliferating and became the bulk of cell resistant to chemotherapy. 
One of the mechanism used by these cells to abrogate uPAR expression could be through the 
DensityEnhanced Phosphatase-1 (DEP-1), which is a receptor-like tyrosine phosphatase. It 
regulates uPAR expression in confluent cells by inhibiting the VEGF-dependent activation of 
ERK1/2, leading to down-regulation of uPAR expression [283]. By contrast, overexpression of 
active ERK1 nullify the DEP-1 effect on uPAR. Therefore, these cells can regain uPAR expression in 
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case of need, and become again actively proliferating. We think that these cells, acquiring 
resistance to chemotherapy and stem traits, using this mechanism to hide uPAR expression, are 
the main responsible for the minimal residual disease. Being also a relatively small number of cells, 
we are actually incapable to monitor and then eradicate such cell population.  Given our 
experience, we think that, regarding novel therapeutic strategy for melanoma treatment, it would 
be better, not to use gene therapies against uPAR but abrogate its function maintaining it 
physically present. For instance, using peptides like M25 [284-286], it would be helpful to 
uncouple uPAR from its partners in order to stop the uPAR-mediated signal transduction, and with 
standard chemotherapies reduce tumor growth and relapse.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
54 
 
Bibliography 
1. Eden G, Archinti M, Furlan F, Ronan M and Degryse B The urokinase Receptor 
Interactome. Curr Pharma Des, 2011, 17, 1874-1889 
2. Andreasen PA, Egelund R, Petersen HH The plasminogen activation system in tumor 
growth, invasion, and metastasis. Cell Mol Life Sci. 2000; 57: 25-40 
3. Danø K, Behrendt N, Høyer-Hansen G, Johnsen M, Lund LR, Ploug M et al. Plasminogen 
activation and cancer. Thromb Haemost. 2005; 93: 676-681 
4. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH Evolving role of uPA/uPAR system in 
human cancers. Cancer Treat Rev. 2008; 34: 122-136 
5. Asuthkar S, Gondi CS, Nalla AK, Velpula KK, Gorantla B, Rao JS Urokinase-type plasminogen 
activator receptor (uPAR)-mediated regulation of WNT/β-catenin signalling is enhanced 
in irradiated medulloblastoma cells. J Biol Chem. 2012; 287: 20576-20589. 
6. Ossowski, L., and J.A. Aguirre-Ghiso. 2000. Urokinase receptor and integrin partnership: 
coordination of signalling for cell adhesion, migration and growth. Curr. Opin. Cell Biol. 
12:613–620 
7. Blasi, F., and P. Carmeliet. 2002. uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. 
Cell Biol.3:932–943 
8. Andreasen, P.A., L. Kjøller, L. Christenson, and M.J. Duffy. 1997. The urokinase- type 
plasminogen activator system in cancer metastasis: a review. Int. J. Cancer. 72:1–22 
9. Wei, Y., M. Lukashev, D.I. Simon, S.C. Bodary, S. Rosenberg, M.V. Doyle, and H.A. 
Chapman. 1996. Regulation of integrin function by the urokinase receptor. Science. 
273:1551–1555. 
10. Wei, Y., J.A. Eble, Z. Wang, J.A. Kreidberg, and H.A. Chapman. 2001. Urokinase receptors 
promote beta1 integrin function through interactions with integrin alpha3beta1. Mol. 
Biol. Cell. 12:2975–2986.  
11. Margheri F, Papucci L, Schiavone N, D'Agostino R, Trigari S, Serratì S, Laurenzana A, 
Biagioni et al. Differential uPAR recruitment in caveolar-lipid rafts by GM1 and GM3 
gangliosides regulates endothelial progenitor cells angiogenesis. J Cell Mol Med. 2015 
Jan;19(1):113-23. Epub 2014 Oct 14. 
12. Llinas P, Le Du MH, Gardsvoll H, et al. Crystal structure of the human urokinase 
plasminogen activator receptor bound to an antagonist peptide. EMBO J 2005; 24: 1655-
63 
55 
 
13. Huang M, Mazar AP, Parry G, Hizagi AA, Kuo A, Cines DB. Crystallization of soluble 
urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143). 
Acta Crystallogr D Biol Crystallogr 2005; 61: 697-700 
14. Barinka C, Parry G, Callahan J, et al. Structural basis of interaction between urokinase-type 
plasminogen activator and its receptor. J Mol Biol 2006; 363: 482-95 
15. Huai Q, Mazar AP, Kuo A, et al. Structure of human urokinase plasminogen activator in 
complex with its receptor. Science 2006; 311: 656-59 
16. Look MP, van Putten WLJ, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled 
analysis of prognostic impact of tumor biological factors uPA and PAI-1 in 8377 breast 
cancer patients. J Natl Cancer Inst. 2002, 94: 116-128. 
17. Schmitt M, Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A, Sweep F, 
Brünner N, Foekens J, Harbeck N: Clinical utility of level-of-evidence-1 disease forecast 
cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn. 2010, 10: 1051-1067. 
18. de Bock CE, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor 
(uPAR) expression in cancer. Med Res Rev. 2004;24:13-39. 
19. O'Halloran TV, Ahn R, Hankins P, Swindell E, Mazar AP. The many spaces of uPAR: delivery 
of theranostic agents and nanobins to multiple tumor compartments through a single 
target. Theranistics 2013;3:496-506. 
20. Del Rosso M, Fibbi G, Pucci M, D'Alessio S, Del Rosso A, Magnelli L, Chiarugi V. Multiple 
pathways of cell invasion are regulated by multiple families of serine proteases. Clin Exp 
Metastasis. 2002;19:193-207. 
21. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 
2010;11:23-36. 
22. Behrendt N, List K, Andreasen PA, Dano K. The pro-urokinase plasminogen-activation 
system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of 
activity through reciprocal pro-enzyme activation. Biochem J. 2003;371:277–287. 
23. Vincenza Carriero M, Franco P, Vocca I, Alfano D, Longanesi-Cattani I, Bifulco K, Mancini 
A, Caputi M, Stoppelli MP. Structure, function and antagonists of urokinase-type 
plasminogen activator. Front Biosci. 2009;14:3782–3794 
24. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signalling: a vascular 
biologist's view. Thromb Haemost. 2007;97:336–342. 
25. Ellis V, Behrendt N, Dano K. Plasminogen activation by receptorbound urokinase. A kinetic 
study with both cell-associated and isolated receptor. 1991;J Biol Chem 266:12752–
12758. 
56 
 
26. Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue 
plasminogen activator. I. Identity with annexin II. J Biol Chem. 1994;269:21191–21197. 
[PubMed] 
27. Andronicos NM, Chen EI, Baik N, Bai H, Parmer CM, Kiosses WB, Kamps MP, Yates JR, III, 
Parmer RJ, Miles LA. Proteomics-based discovery of a novel, structurally unique, and 
developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell 
surface plasminogen activation. Blood. 2010;115:1319–1330. 
28. Quigley JP, Gold LI, Schwimmer R, Sullivan LM. Limited cleavage of cellular fibronectin by 
plasminogen activator purified from transformed cells. Proc Natl Acad Sci USA. 
1987;84:2776–2780. 
29. Goldfinger LE, Stack MS, Jones JC. Processing of laminin-5 and its functional 
consequences: role of plasmin and tissue-type plasminogen activator. J Cell 
Biol. 1998;141:255–265. 
30. Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci. 2002;115:3861–3863. 
31. Murphy G, Stanton H, Cowell S, Butler G, Knauper V, Atkinson S, Gavrilovic J. Mechanisms 
for pro matrix metalloproteinase activation. APMIS. 1999;107:38–44. 
32. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP. Activation 
of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade 
enhances tumor cell invasion. J Biol Chem. 1999;274:13066–13076. 
33. Waver AM, Hussaini IM, Mazar A, Henkin J, Gonias SL. Embryonic fibroblast that are 
genetically deficient in low density lipoprotein receptor-related protein demonstrate 
increased activity of the urokinase receptor system and accelerated migration on 
vitronectin. J Biol Chem 1997; 272: 14372-9 
34. Nykjaer A, Petersen CM, Moller B, et al. Purified α2-macroglobulin receptor/LDL receptor-
related protein bins urokinase plasminogen activator inhibition type-1 complex. Evidence 
that the α2-macroglobulin receptor mediates cellular degradation of urokinase receptor-
bound complexes. J Biol Chem 1992; 267: 14543-6 
35. Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ. Plasminogen activator inhibitor-1 
detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003; 160: 
781-91 
36. Schvartz I, Seger D, Shaltiel S. Vitronectin. Int J Biochem Cell Biol 1999; 31: 539-44. 
37. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the 
urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380-
8. 
57 
 
38. Ciambrone GJ, McKeown-Longo PJ. Vitronectin regulates the synthesis and localization of 
urokinase-type plasminogen activator in HT-1080 cells. J Biol Chem 1992; 267: 13617-22. 
39. Gårdsvoll H, Ploug M. Mapping of the vitronectin-binding site on the urokinase receptor: 
involvement of a coherent receptor interface consisting of residues from both domain I 
and the flanking interdomain linker region. J Biol Chem 2007; 282: 13561-72. 
40. Degryse B, Orlando S, Resnati M, Rabbani, SA, Blasi, F. Urokinase/urokinase receptor and 
vitronectin/αvβ3 integrin induce chemotaxis and cytoskeleton reorganization through 
different signalling pathways. Oncogene 2001; 20: 2032-43. 
41. Sidenius N, Blasi F. Domain 1 of the urokinase receptor (uPAR) is required for uPAR-
mediated cell binding to vitronectin. FEBS Lett 2000; 470: 40-6. 
42. Muir E, Du JS, Fok-Seang J, et al. Increased axon growth through astrocyte cell lines 
transfected with urokinase. Glia 1998; 23: 24-34. 
43. Deng G, Royle G, Wang S, Crain K, Loskutoff DJ. Structural and functional analysis of the 
plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of 
vitronectin. J Biol Chem 1996; 271: 12716-23. 
44. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin 
alpha V beta 3 binding to vitronectin. Nature 1996; 383: 441-3. 
45. Minor KH, Peterson CB. Plasminogen activator inhibitor type 1 promotes the self-
association of vitronectin into complexes exhibiting altered incorporation into the 
extracellular matrix. J Biol Chem 2002; 277: 10337-45. 
46. Kamikubo Y, Neels JG, Degryse B. Vitronectin inhibits plasminogen activator inhibitor-1-
induced signalling and chemotaxis by blocking plasminogen activator inhibitor-1 binding 
to the lowdensity lipoprotein receptor-related protein. Int J Biochem Cell Biol 2009; 41: 
578-85. 
47. Garg N, Goyal N, Strawn TL, et al. Plasminogen activator inhibitor-1 and vitronectin 
expression level and stoichiometry regulate vascular smooth muscle cell migration 
through physiological collagen matrices. J Thromb Haemost 2010; 8: 1847-54. 
48. Zaidel-Bar R, Itzkovitz S, Ma'ayan A, Iyengar R, Geiger B. Functional atlas of the integrin 
adhesome. Nat Cell Biol 2007; 9: 858-67. 
49. Tarui T, Mazar AP, Cines DB, Takada Y. Urokinase-type plasminogen activator receptor 
(CD87) is a ligand for integrins and mediates cell-cell interaction. J Biol Chem 2001; 276: 
3983-90. 
50. Wei Y, Czekay RP, Robillard L, et al. Regulation of α5β1 integrin conformation and function 
by urokinase receptor binding. J Cell Biol 2005; 168: 501-11. 
58 
 
51. Simon DI, Rao NK, Xu H, et al. Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) 
form a functional unit on monocytic cells. Blood 1996; 88: 3185-94. 
52. Yebra M, Parry GC, Strömblad S, et al. Requirement of receptorbound urokinase-type 
plasminogen activator for integrin αvβ5-directed cell migration. J Biol Chem. 1996 Nov 
15;271(46):29393-9. 
53. Chavakis T, May AE, Preissner KT, Kanse SM. Molecular mechanisms of zinc-dependent 
leukocyte adhesion involving the urokinase receptor and β2-integrins. Blood 1999; 93: 
2976-83. 
54. Silvestri I, Longanesi Cattani I, Franco P, et al. Engaged urokinase receptors enhance tumor 
breast cell migration and invasion by upregulating αvβ5 vitronectin receptor cell surface 
expression. Int J Cancer 2002; 102: 562-71. 
55. Margheri F, Manetti M, Serratì S, et al. Domain 1 of the urokinase type plasminogen 
activator receptor is required for its morphologic and functional, β2 integrin-mediated 
connection with actin cytoskeleton in human microvascular endothelial cells: failure of 
association in systemic sclerosis endothelial cells. Arthritis Rheum 2006; 54: 3926-38. 
56. Pluskota E, Soloviev DA, Plow EF. Convergence of the adhesive and fibrinolytic systems: 
recognition of urokinase by integrin αMβ2 as well as by the urokinase receptor regulates 
cell adhesion and migration. Blood 2003; 101: 1582-90. 
57. Pluskota E, Soloviev DA, Bdeir K, Cines DB, Plow EF. Integrin αMβ2 orchestrates and 
accelerates plasminogen activation and fibrinolysis by neutrophils. J Biol Chem 2004; 279: 
18063-72. 
58. Demetriou MC, Pennington ME, Nagle RB, Cress AE. Extracellular α6 integrin cleavage by 
urokinase-type plasminogen activator in human prostate cancer. Exp Cell Res 2004; 294: 
550-8. 
59. Kwak SH, Mitra S, Bdeir K, et al. The kringle domain of urokinase-type plasminogen 
activator potentiates LPS-induced neutrophil activation through interaction with αvβ3 
integrins. J Leukoc Biol 2005; 78: 937-45. 
60. Franco P, Vocca I, Carriero MV, et al. Activation of urokinase receptor by a novel 
interaction between the connecting peptide region of urokinase and αvβ5 integrin. J Cell 
Sci 2006; 119: 3424-34. 
61. Tarui T, Akakura N, Majumdar M, et al. Direct interaction of the kringle domain of 
urokinase-type plasminogen activator (uPA) and integrin αvβ3 induces signal transduction 
and enhances plasminogenactivation. Thromb Haemost 2006; 95: 524-34. 
59 
 
62. Degryse B, Fernandez-Recio J, Citro V, Blasi F, Cubellis MV. In silico docking of urokinase 
plasminogen activator and integrins. BMC Bioinformatics 2008 
63. Degryse B, Resnati M, Rabbani SA, Villa A, Fazioli F, Blasi F. Src-dependence and pertussis-
toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton 
reorganization in rat smooth muscle cells. Blood 1999; 94: 649-62. 
64. Chapman HA, Wei Y, Simon DI, Waltz DA. Role of urokinase receptor and caveolin in 
regulation of integrin signalling. Thromb Haemost 1999; 82: 291-7. 
65. Wei Y, Yang X, Liu Q, Wilkins JA, Chapman HA. A role for caveolin and the urokinase 
receptor in integrin-mediated adhesion and signalling. J Cell Biol 1999; 144: 1285-94. 
66. Schwab W, Gavlik JM, Beichler T, et al. Expression of the urokinase-type plasminogen 
activator receptor in human articular chondrocytes: association with caveolin and β1-
integrin. Histochem  Cell Biol 2001; 115: 317-23. 
67. Chintala SK, Mohanam S, Go Y, et al. Altered in vitro spreading and cytoskeletal 
organization in human glioma cells by downregulation of urokinase receptor. Mol 
Carcinog 1997; 20: 355-65. 
68. Abu-Ali S, Sugiura T, Takahashi M, et al. Expression of the urokinase receptor regulates 
focal adhesion assembly and cell migration in adenoid cystic carcinoma cells. J Cell Physiol 
2005; 203: 410-9. 
69. Xue W, Mizukami I, Todd RF 3rd, Petty HR. Urokinase-type plasminogen activator 
receptors associate with β1 and β3 integrins of fibrosarcoma cells: dependence on 
extracellular matrix components. Cancer Res 1997; 57: 1682-9. 
70. May AE, Neumann FJ, Schömig A, Preissner KT. VLA-4 α4β1 engagement defines a novel 
activation pathway for β2 integrin-dependent leukocyte adhesion involving the urokinase 
receptor. Blood 2000; 96: 506-13. 
71. Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res. 2010 Jan;339(1): 269-80 
72. Liu D, Aguirre Ghiso J, Estrada Y, Ossowski L. EGFR is a transducer of the urokinase 
receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer 
Cell 2002; 1: 445-57. 
73. Kiyan J, Kiyan R, Haller H, Dumler I. Urokinase-induced signalling in human vascular 
smooth muscle cells is mediated by PDGFR- β. EMBO J 2005; 24: 1787-97. 
74. Gallicchio MA, Kaun C, Wojta J, Binder B, Bach LA. Urokinase type plasminogen activator 
receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma 
cells in vitro. J Cell Physiol 2003; 197: 131-8. 
60 
 
75. Bauer TW, Fan F, Liu W, et al. Insulin-like growth factor-I-mediated migration and invasion 
of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen 
activator receptor. Ann Surg 2005; 241: 748-56. 
76. Bauer TW, Liu W, Fan F, et al. Targeting of urokinase plasminogen activator receptor in 
human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I 
receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer 
Res 2005; 65: 7775-81. 
77. Guerrero J, Santibañez JF, González A, Martínez J. EGF receptor transactivation by 
urokinase receptor stimulus through a mechanism involving Src and matrix 
metalloproteinases. Exp Cell Res 2004; 292: 201-8. 
78. LaRusch GA, Mahdi F, Shariat-Madar Z, et al. Factor XII stimulates ERK1/2 and Akt through 
uPAR, integrins, and the EGFR to initiate angiogenesis. Blood 2010; 115: 5111-20. 
79. Jo M, Thomas KS, Marozkina N, et al. Dynamic assembly of the urokinase-type 
plasminogen activator signalling receptor complex determines the mitogenic activity of 
urokinase-type plasminogen activator. J Biol Chem 2005; 280: 17449-57. 
80. Jo M, Thomas KS, O'Donnell DM, Gonias SL. Epidermal growth factor receptor-dependent 
and -independent cell-signalling pathways originating from the urokinase receptor. J Biol 
Chem 2003; 278: 1642-6. 
81. Wang XQ, Sun P, Paller AS. Gangliosides inhibit urokinase-type plasminogen activator 
(uPA)-dependent squamous carcinoma cell migration by preventing uPA receptor/α5β1 
integrin/epidermal growth factor receptor interactions. J Invest Dermatol 2005; 124: 839-
48. 
82. Nicholl SM, Roztocil E, Davies MG. Urokinase-induced smooth muscle cell responses 
require distinct signalling pathways: a role for the epidermal growth factor receptor. J 
Vasc Surg 2005; 41: 672-81. 
83. Monaghan-Benson E, McKeown-Longo PJ. Urokinase-type plasminogen activator receptor 
regulates a novel pathway of fibronectin matrix assembly requiring Src-dependent 
transactivation of epidermal growth factor receptor. J Biol Chem 2006; 281: 9450-9. 
84. Bakken AM, Protack CD, Roztocil E, Nicholl SM, Davies MG. Cell migration in response to 
the amino-terminal fragment of urokinase requires epidermal growth factor receptor 
activation through an ADAM-mediated mechanism. J Vasc Surg 2009; 49: 1296-303. 
85. D'Alessio S, Gerasi L, Blasi F. uPAR-deficient mouse keratinocytes fail to produce EGFR-
dependent laminin-5, affecting migration in vivo and in vitro. J Cell Sci 2008; 121: 3922-
32. 
61 
 
86. Grimaldi G, Di Fiore P, Locatelli EK, Falco J, Blasi F. Modulation of urokinase plasminogen 
activator gene expression during the transition from quiescent to proliferative state in 
normal mouse cells. EMBO J 1986; 5: 855-61. 
87. Boyd D. Examination of the effects of epidermal growth factor on the production of 
urokinase and the expression of the plasminogen activator receptor in a human colon 
cancer cell line. Cancer Res 1989; 49: 2427-32. 
88. Amos S, Redpath GT, Dipierro CG, Carpenter JE, Hussaini IM. Epidermal growth factor 
receptor-mediated regulation of urokinase plasminogen activator expression and 
glioblastoma invasion via CSRC/MAPK/AP-1 signalling pathways. J Neuropathol Exp 
Neurol 2010; 69: 582-92. 
89. Baek MK, Kim MH, Jang HJ, et al. EGF stimulates uPAR expression and cell invasiveness 
through ERK, AP-1, and NF-kappaB signalling in human gastric carcinoma cells. Oncol Rep 
2008; 20: 1569-75. 
90. Smith PC, Santibañez JF, Morales JP, Martinez J. Epidermal growth factor stimulates 
urokinase-type plasminogen activator expression in human gingival fibroblasts. Possible 
modulation by genistein and curcumin. J Periodontal Res 2004; 39: 380-7. 
91. Sandberg T, Ehinger A, Casslén B. Paracrine stimulation of capillary endothelial cell 
migration by endometrial tissue involves epidermal growth factor and is mediated via up-
regulation of the urokinase plasminogen activator receptor. J Clin Endocrinol Metab 2001; 
86: 1724-30. 
92. Adina Vultur, Meenhard Herlyn. SnapShot: Melanoma Cancer Cell Volume 23, Issue 5, 
706, 13 May 2013 
93. Haass NK, Smalley KS, Herlyn M. The role of altered cell-cell communication in melanoma 
progression. J Mol Histol. 2004 Mar; 35(3):309-18 
94. Clark WH Jr, Elder DE, Guerry D 4th, Epstein MN, Greene MH, Van Horn M. A study of 
tumor progression: the precursor lesions of superficial spreading and nodular melanoma. 
Hum Pathol. 1984 Dec; 15(12):1147-65  
95. Gaggioli C, Sahai E. Melanoma invasion - current knowledge and future directions. 
Pigment Cell Res. 2007 Jun;20(3):161-72 
96. Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev 
Cancer. 2003 Aug; 3(8):559-70 
97. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett 
MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, 
Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, 
62 
 
Jayatilake H, Gusterson BA, Cooper C, Shipley J,Hargrave D, Pritchard-Jones K, Maitland N, 
Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, 
Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall 
CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. 
Nature. 2002 Jun 27; 417(6892):949-54 
98. Gray-Schopfer VC, da Rocha Dias S, Marais R. The role of B-RAF in melanoma. Cancer 
Metastasis Rev. 2005 Jan; 24(1):165-83. Review. Erratum in: Cancer Metastasis Rev. 2005 
Jun; 24(2):367 
99. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the 
genomic era. Genes Dev. 2006 Aug 15; 20(16):2149-82 
100. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 
2004 Oct; 6(4):313-9 
101. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, 
Marshall CJ, Springer CJ, Barford D, Marais R; Cancer Genome Project. Mechanism of 
activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004 
Mar 19; 116(6):855-67 
102. Woods D, Cherwinski H, Venetsanakos E, Bhat A, Gysin S, Humbert M, Bray PF, 
Saylor VL, McMahon M. Induction of beta3-integrin gene expression by sustained 
activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling 
pathway. Mol Cell Biol. 2001 May; 21(9):3192-205 
103. Huntington JT, Shields JM, Der CJ, Wyatt CA, Benbow U, Slingluff CL Jr, 
Brinckerhoff CE. Overexpression of collagenase 1 (MMP-1) is mediated by the ERK 
pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor 
signaling. J Biol Chem. 2004 Aug 6; 279(32):33168-76 
104. Sumimoto H, Miyagishi M, Miyoshi H, Yamagata S, Shimizu A, Taira K, Kawakami 
Y. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF 
with lentivirus-mediated RNA interference. Oncogene. 2004 Aug12; 23(36):6031-9 
105. Liang S, Sharma A, Peng HH, Robertson G, Dong C. Targeting mutant (V600E) B-
Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma 
extravasation. Cancer Res. 2007 Jun 15; 67(12):5814-20 
106. Orgaz JL, Sanz-Moreno V. Emerging molecular targets in melanoma invasion and 
metastasis. Pigment Cell Melanoma Res. 2013 Jan; 26(1):39-57 
107. Giorgio Parmiani. Melanoma Cancer Stem Cells: Markers and Functions. Cancers 
(Basel). 2016 Mar; 8(3): 34. 
63 
 
108. Fang D., Nguyen T.K., Lishear K., Finko R., Kulp A.N., Hotz S., Van Belle P.A., Xu X., 
Elder D.E., Herlyn M. A tumorigenic subpopulation with stem cell property in melanomas. 
Cancer Res. 2005;65:9228–9237. 
109. Singh S., Clarke J.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. 
Identification of a cance stem cells in human brain tumors. Cancer Res. 2003;63 
110. Tirino V., Desiderio V., Paino F., De Rosa A. Human primary bone sarcoma contain 
CD133. Cancer Stem Cells. FASEB J. 2011;25:2022–2030. 
111. Desiderio V., Papagerakis P., Tinino V., Zheng L., Matossian M., Prince M.E., Paino 
F., Mele L., Papaccio F., Montella R. Increased fucosylation has a pivotal role in invasive 
and metastatic properties of head and neck cancer stem cells. Oncotarget. 2014;6:71–84. 
112. Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., Conticello C., Ruco 
L., Peschle C., de Maria P. Identification and expression of the tumorigenic lung cancer. 
Cell Death Differ. 2008;15:504–514. 
113. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. 
Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA. 
2003;100:3983–3988. 
114. Quintana E., Schakleton M., Foster H.R., Fullen D.R., Sabel M.S., Johnson T.M., 
Morrison S.J. Phenotypic heterogeneity among tumorienic melanoma cells from patients 
that is reversibile and not hierarchically organized. Cancer Cell. 2010;18:510–523. 
115. Perego M., Tortoreto M., Tragni G., Mariani L., Deho P., Carbone A., Santinami M., 
Patuzzo R., Della Mina P., Villa A., et al. Heterogeneous phenotype of human melanoma 
cells with in vitro and in vivo features of tumor-initiating cells. J. Invest. Dermatol. 2010 
116. Held M.A., Curley D.P., Dankort D., McMahon M., Muthusamy V., Boserberg M.W. 
Characterization of melanoma cells capable of propagating tumors from a single cells. 
Cancer Res. 2010;70:388–397. 
117. Singh, S. K. et al. Identification of human brain tumour-initiating cells. Nature 432, 
396–401 (2004). 
118. O'Brien, C. A., Pollett, A., Gallinger, S. & Dick, J. E. A human colon cancer cell 
capable of initiating tumour growth in immunodeficient mice. Nature 445, 106–110 
(2007). 
119. Ricci-Vitiani, L. et al. Identification and expansion of human colon-cancer-
initiating cells. Nature 445, 111–115 (2007). 
120. Li, C. et al. Identification of pancreatic cancer stem cells. Cancer Res. 67, 1030–
1037 (2007). 
64 
 
121. Schatton, T. et al. Identification of cells initiating human melanomas. Nature 451, 
345–349 (2008). 
122. Yang, Z. F. et al. Significance of CD90+ cancer stem cells in human liver cancer. 
Cancer Cell 13, 153–166 (2008). 
123. Bin-Bing S. Zhou, Haiying Zhang, Marc Damelin, Kenneth G. Geles, Justin C. 
Grindley& Peter B. DirksTumour-initiating cells: challenges and opportunities for 
anticancer drug discovery. Nature Reviews Drug Discovery 8, 806-823 (October 2009) 
124. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted 
therapy. Nature. 2007 Feb 22;445(7130):851-7. 
125. Wiedenheft, B., Sternberg, S.H. & Doudna, J.A. RNA-guided genetic silencing 
systems in bacteria and archaea. Nature 482, 331–338 (2012). 
126. Fineran, P.C. & Charpentier, E. Memory of viral infections by CRISPR-Cas adaptive 
immune systems: acquisition of new information. Virology 434, 202–209 (2012). 
127. Horvath, P. & Barrangou, R. CRISPR/Cas, the immune system of bacteria and 
archaea. Science 327, 167–170 (2010). 
128. Barrangou, R. et al. CRISPR provides acquired resistance against viruses in 
prokaryotes. Science 315, 1709–1712 (2007). 
129. Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A. Nucleotide sequence of 
the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, 
and identification of the gene product. Journal of Bacteriology. 169(12): 5429–33. 
130. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for 
genome engineering. Cell. 157 (6): 1262–78.doi:10.1016/j.cell.2014.05.010. 
131. van Soolingen D, de Hass PE, Hermans PW, Groenen PM, van Embden JD. 
Comparison of various repetitive DNA elements as genetic markers for strain 
differentiation and epidemiology of Mycobacterium tuberculosis. J Clin Microbiol. 31 (8): 
1987–95. 
132. Mojica FJ, Ferrer C, Juez G, Rodríguez-Valera F. Long stretches of short tandem 
repeats are present in the largest replicons of the Archaea Haloferax mediterranei and 
Haloferax volcanii and could be involved in replicon partitioning. Molecular Microbiology. 
17: 85–93. doi:10.1111/j.1365-2958.1995.mmi_17010085.x. 
133. Pourcel C, Salvignol G, Vergnaud G CRISPR elements in Yersinia pestis acquire new 
repeats by preferential uptake of bacteriophage DNA, and provide additional tools for 
evolutionary studies. Microbiology. 151 (Pt 3): 653–63.doi:10.1099/mic.0.27437-0. 
65 
 
134. Mojica FJ, Díez-Villaseñor C, García-Martínez J, Soria E. Intervening sequences of 
regularly spaced prokaryotic repeats derive from foreign genetic elements. Journal of 
Molecular Evolution. 60 (2): 174–82. doi:10.1007/s00239-004-0046-3. 
135. Bolotin A, Quinquis B, Sorokin A, Ehrlich SD. Clustered regularly interspaced short 
palindrome repeats (CRISPRs) have spacers of extrachromosomal origin". Microbiology. 
151 (Pt 8): 2551–61. doi:10.1099/mic.0.28048-0. 
136. Makarova KS, Grishin NV, Shabalina SA, Wolf YI, Koonin EV. A putative RNA-
interference-based immune system in prokaryotes: computational analysis of the 
predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and 
hypothetical mechanisms of action". Biology Direct. 1: 7. doi:10.1186/1745-6150-1-7. 
137. Brouns SJ1, Jore MM, Lundgren M, Westra ER, Slijkhuis RJ, Snijders AP, Dickman 
MJ, Makarova KS, Koonin EV, van der Oost J. Small CRISPR RNAs guide antiviral defense in 
prokaryotes. Science. 2008 Aug 15;321(5891):960-4. doi: 10.1126/science.1159689. 
138. Marraffini LA. CRISPR-Cas immunity in prokaryotes. Nature. 526 (7571): 55–61. 
doi:10.1038/nature15386. 
139. Garneau JE, Dupuis M, Villion M, Romero DA, Barrangou R, Boyaval P, Fremaux C, 
Horvath P, Magadán AH, Moineau S. The CRISPR/Cas bacterial immune system cleaves 
bacteriophage and plasmid DNA. Nature. 468 (7320): 67–71.doi:10.1038/nature09523. 
140. Deltcheva, E. et al. CRISPR RNA maturation by trans-encoded small RNA and host 
factor RNase III. Nature 471, 602–607 (2011). 
141. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive 
bacterial immunity. Science 337, 816–821 (2012). 
142. Jeffry D Sander & J Keith Joung. CRISPR-Cas systems for editing, regulating and 
targeting genomes. Nature Biotechnology 32, 347–355 (2014) doi:10.1038/nbt.2842 
143. Jiang, W., Bikard, D., Cox, D., Zhang, F. & Marraffini, L.A. RNA-guided editing of 
bacterial genomes using CRISPR-Cas systems. Nat. Biotechnol. 31, 233–239 (2013). 
144. Pattanayak, V. et al. High-throughput profiling of off-target DNA cleavage reveals 
RNA-programmed Cas9 nuclease specificity. Nat. Biotechnol. 31, 839–843 (2013). 
145. Mali, P. et al. RNA-guided human genome engineering via 
Cas9. Science 339, 823–826(2013). 
146. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas 
systems. Science 339, 819–823 (2013). 
66 
 
147. Jinek, M. et al. RNA-programmed genome editing in human 
cells. Elife 2, e00471 (2013). 
148. Cho, S.W., Kim, S., Kim, J.M. & Kim, J.S. Targeted genome engineering in human 
cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 31, 230–232 (2013). 
149. Hwang, W.Y. et al. Efficient genome editing in zebrafish using a CRISPR-Cas 
system. Nat. Biotechnol. 31, 227–229 (2013). 
150. F Ann Ran, Patrick D Hsu, Jason Wright, Vineeta Agarwala, David A Scott & Feng 
Zhang. Genome engineering using the CRISPR-Cas9 system. Nature Protocols 8, 2281–
2308 (2013) 
151. Anders C, Niewoehner O, Duerst A, Jinek M. Structural basis of PAM-dependent 
target DNA recognition by the Cas9 endonuclease. Nature. 2014 Sep 25;513(7519):569-
73. 
152. Nishimasu H, Ran FA, Hsu PD, Konermann S, Shehata SI, Dohmae N, Ishitani R, 
Zhang F, Nureki O. Crystal structure of Cas9 in complex with guide RNA and target DNA. 
Cell. 2014 Feb 27;156(5):935-49. 
153. Haft, D.H., Selengut, J., Mongodin, E.F. & Nelson, K.E. A guild of 45 CRISPR-
associated (Cas) protein families and multiple CRISPR/Cas subtypes exist in prokaryotic 
genomes. PLoS Comput. Biol. 1, e60 (2005). 
154. Gasiunas, G., Barrangou, R., Horvath, P. & Siksnys, V. Cas9-crRNA 
ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in 
bacteria. Proc. Natl. Acad. Sci. USA 109, E2579–E2586 (2012). 
155. Sapranauskas, R. et al. The Streptococcus thermophilus CRISPR/Cas system 
provides immunity in Escherichia coli. Nucleic Acids Res. 39, 9275–9282 (2011). 
156. Fu, Y., Sander, J.D., Reyon, D., Cascio, V.M. & Joung, J.K. Improving CRISPR-Cas 
nuclease specificity using truncated guide RNAs. Nat. Biotechnol. 
157. Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas 
nucleases in human cells. Nat. Biotechnol. 31, 822–826 (2013). 
158. Hsu, P.D. et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. 
Biotechnol.31, 827–832 (2013). 
159. Semenova, E. et al. Interference by clustered regularly interspaced short 
palindromic repeat (CRISPR) RNA is governed by a seed sequence. Proc. Natl. Acad. Sci. 
USA 108, 10098–10103 (2011). 
67 
 
160. Mali, P., et al. CAS9 transcriptional activators for target specificity screening and 
paired nickases for cooperative genome engineering. Nat. Biotechnol. 31, 833–838 
(2013). 
161. Cradick, T.J., Fine, E.J., Antico, C.J. & Bao, G. CRISPR/Cas9 systems targeting beta-
globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res. 41, 9584–
9592 (2013). 
162. Ding, Q. et al. Enhanced efficiency of human pluripotent stem cell genome editing 
through replacing TALENs with CRISPRs. Cell Stem Cell 12, 393–394 
163. Ran, F.A. et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome 
editing specificity. Cell 154, 1380–1389 
164. Cho, S.W. et al. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided 
endonucleases and nickases. Genome Res. 24, 132–141 
165. Kuzminov, A. Single-strand interruptions in replicating chromosomes cause 
double-strand breaks. Proc. Natl. Acad. Sci. USA 98, 8241–8246 
166. Cortes-Ledesma, F. & Aguilera, A. Double-strand breaks arising by replication 
through a nick are repaired by cohesin-dependent sister-chromatid exchange. EMBO Rep. 
7, 919–926 
167. Wang, T., Wei, J.J., Sabatini, D.M. & Lander, E.S. Genetic screens in human cells 
using the CRISPR-Cas9 system. Science 343, 80–84 
168. Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. 
Science343, 84–87 
169. Koike-Yusa, H., Li, Y., Tan, E.P., Velasco-Herrera, M.D.C. & Yusa, K. Genome-wide 
recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. 
Nat. Biotechnol. 32, 267–273 
170. Li, D. et al. Heritable gene targeting in the mouse and rat using a CRISPR-Cas 
system. Nat. Biotechnol. 31, 681–683 
171. Yu, Z. et al. Highly efficient genome modifications mediated by CRISPR/Cas9 in 
Drosophila. Genetics 195, 289–291 
172. Bassett, A.R., Tibbit, C., Ponting, C.P. & Liu, J.L. Highly efficient targeted 
mutagenesis of Drosophila with the CRISPR/Cas9 system. Cell Reports 4, 220–228 
173. Friedland, A.E. et al. Heritable genome editing in C. elegans via a CRISPR-Cas9 
system. Nat. Methods 10, 741–743 
174. Gratz, S.J. et al. Genome engineering of Drosophila with the CRISPR RNA-guided 
Cas9 nuclease. Genetics 194, 1029–1035  
68 
 
175. Lo, T.W. et al. Precise and heritable genome editing in evolutionarily diverse 
nematodes using TALENs and CRISPR/Cas9 to engineer insertions and deletions. Genetics 
195, 331–348  
176. Waaijers, S. et al. CRISPR/Cas9-targeted mutagenesis in Caenorhabditis elegans. 
Genetics195, 1187–1191 
177. Tzur, Y.B. et al. Heritable custom genomic modifications in Caenorhabditis elegans 
via a CRISPR-Cas9 system. Genetics 195, 1181–1185 
178. Katic, I. & Grosshans, H. Targeted heritable mutation and gene conversion by 
Cas9-CRISPR in Caenorhabditis elegans. Genetics 195, 1173–1176 
179. Chiu, H., Schwartz, H.T., Antoshechkin, I. & Sternberg, P.W. Transgene-free 
genome editing in Caenorhabditis elegans using CRISPR-Cas. Genetics 195, 1167–1171 
180. Li, J.F. et al. Multiplex and homologous recombination-mediated genome editing 
in Arabidopsis and Nicotiana benthamiana using guide RNA and Cas9. Nat. Biotechnol. 31, 
688–691 
181. Nekrasov, V., Staskawicz, B., Weigel, D., Jones, J.D. & Kamoun, S. Targeted 
mutagenesis in the model plant Nicotiana benthamiana using Cas9 RNA-guided 
endonuclease. Nat. Biotechnol. 31, 691–693 
182. Shan, Q. et al. Targeted genome modification of crop plants using a CRISPR-Cas 
system. Nat. Biotechnol. 31, 686–688 
183. Xie, K. & Yang, Y. RNA-guided genome editing in plants using a CRISPR-Cas system. 
Mol. Plant 6, 1975–1983 
184. Jiang, W. et al. Demonstration of CRISPR/Cas9/sgRNA-mediated targeted gene 
modification in Arabidopsis, tobacco, sorghum and rice. Nucleic Acids Res. 41, e188 
185. Urnov, F.D., Rebar, E.J., Holmes, M.C., Zhang, H.S. & Gregory, P.D. Genome editing 
with engineered zinc finger nucleases. Nat. Rev. Genet. 11, 636–646 
186. Bikard, D. et al. Programmable repression and activation of bacterial gene 
expression using an engineered CRISPR-Cas system. Nucleic Acids Res. 41, 7429–7437 
187. Qi, L.S. et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific 
control of gene expression. Cell 152, 1173–1183 
188. Maeder, M.L. et al. CRISPR RNA-guided activation of endogenous human genes. 
Nat. Methods 10, 977–979 
189. Perez-Pinera, P. et al. RNA-guided gene activation by CRISPR-Cas9-based 
transcription factors. Nat. Methods 10, 973–976 
69 
 
190. Konermann, S. et al. Optical control of mammalian endogenous transcription and 
epigenetic states. Nature 500, 472–476  
191. Cheng, A.W. et al. Multiplexed activation of endogenous genes by CRISPR-on, an 
RNA-guided transcriptional activator system. Cell Res. 23, 1163–1171 
192. Gilbert, L.A. et al. CRISPR-mediated modular RNA-guided regulation of 
transcription in eukaryotes. Cell 154, 442–451 
193. Chen, B. et al. Dynamic imaging of genomic loci in living human cells by an 
optimized CRISPR/Cas system. Cell 155, 1479–1491 
194. Esvelt, K.M. et al. Orthogonal Cas9 proteins for RNA-guided gene regulation and 
editing. Nat. Methods 10, 1116–1121 
195. Hou, Z. et al. Efficient genome engineering in human pluripotent stem cells using 
Cas9 from Neisseria meningitidis. Proc. Natl. Acad. Sci. USA 110, 15644–15649 
196. Benjamin Beck and Cédric Blanpain. Unravelling cancer stem cell potential. Nature 
Reviews Cancer 13, 727–738 (2013) 
197. Shaheenah Dawood, Laura Austin, and Massimo CristofanilliCancer Stem Cells: 
Implications for Cancer Therapy. Oncology (Williston Park). 2014 Dec;28(12):1101-7, 1110 
198. Antonija Kreso and John E. DickEvolution of the Cancer Stem Cell Model. Stem 
Cell. 2014 Mar 6;14(3):275-91. 
199. Mazar AP, Ahn RW, O’Halloran TV. Development of novel therapeutics targeting 
the urokinase plasminogen activator receptor (uPAR) and their translation toward the 
clinic. Current pharmaceutical design. 2011; 17: 1970-1978 
200. Margheri F, Luciani C, Taddei ML, Giannoni E, Laurenzana A, Biagioni A, Chillà A, 
Chiarugi P, Fibbi G, Del Rosso M. The receptor for urokinase-plasminogen activator (uPAR) 
controls plasticity of cancer cell movement in mesenchymal and amoeboid migration 
style. Oncotarget. 2014;5:1538-53.  
201. Laurenzana A, Biagioni A, D'Alessio S, Bianchini F, Chillà A, Margheri F, Luciani C, 
Mazzanti B, Pimpinelli N, Torre E, Danese S, Calorini L, Del Rosso M, Fibbi G. Melanoma 
cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading 
enzyme. Oncotarget. 2014;5:3711-27. 
202. Laurenzana A, Biagioni A, Bianchini F, Peppicelli S, Chillà A, Margheri F, Luciani C, 
Pimpinelli N, Del Rosso M, Calorini L, Fibbi G. Inhibition of uPAR-TGFβ crosstalk blocks 
MSC-dependent EMT in melanoma cells. J Mol Med (Berl). 2015 Jul;93(7):783-94. 
203. Reya T, Morrison SJ, Clarke MF, Weissman IL.Stem cells, cancer, and cancer stem 
cells. Nature 2001;414:105–11 
70 
 
204. Hendrix M, Seftor EA, Meltzer PS, et al. The stem cell plasticity of aggressive 
melanoma tumor cells. In: S Sell. Stem cells handbook. Totowa (NJ): Humana Press, Inc.; 
2003. p. 297–306. 
205. Reed JA, Finnerty B, Albino AP. Divergent cellular differentiation pathways during 
the invasive stage of cutaneous malignant melanoma progression. Am J Pathol 
1999;155:549–55. 
206. Fang D, Hallman J, Sangha N, et al. Expression of microtubule-associated protein 
2 in benign and malignant melanocytes: implications for differentiation and progression 
of cutaneous melanoma. Am J Pathol 2001; 158:2107–15. 
207. Maria Vinci, Sharon Gowan, Frances Boxall, Lisa Patterson, Miriam Zimmermann, 
William Court, Cara Lomas, Marta Mendiola, David Hardisson and Suzanne A 
EcclesAdvances in establishment and analysis of three-dimensional tumor spheroid-based 
functional assays for target validation and drug evaluation. BMC Biology201210:29 
208. Sreelatha Gopinath, Rama Rao Malla, Christopher S. Gondi, Kiranmai Alapati, 
Daniel Fassett, Jeffrey D. Klopfenstein et al. Co-Depletion of Cathepsin B and uPAR Induces 
G0/G1 Arrest in Glioma via FOXO3a Mediated p27Kip1 Upregulation PLoS One. 2010 Jul 
22;5(7):e11668. 
209. Jones SM, Kazlauskas A. Growth-factor-dependent mitogenesis requires two 
distinct phases of signalling. Nat Cell Biol 3: 165-172, 2001 
210. Lui VW, Grandis JREGFR-mediated cell cycle regulation. Anticancer Res. 2002 Jan-
Feb;22(1A):1-11. 
211. Tiffany E. Taylor, Frank B. Furnari and Webster K. CaveneeTargeting EGFR for 
Treatment of Glioblastoma: Molecular Basis to Overcome ResistanceCurr Cancer Drug 
Targets. 2012 Mar; 12(3): 197–209. 
212. Harding J, Burtness B.Cetuximab: an epidermal growth factor receptor chemeric 
human-murine monoclonal antibody.Drugs Today (Barc). 2005 Feb;41(2):107-27. 
213. James A. Ramirez, Joan Guitart, M. Sambasiva Rao, Leslie K. DiazCyclin D1 
expression in melanocytic lesions of the skin. Annals of Diagnostic Pathology Volume 9, 
Issue 4, August 2005, 185–188 
214. Ren S, Rollins BJ. Cyclin C/cdk3 promotes Rb-dependent G0 exit. Cell. 
2004;117:239–51. 
215. Rickert P, Seghezzi W, Shanahan F, Cho H, Lees E. Cyclin C/CDK8 is a novel CTD 
kinase associated with RNA polymerase II. Oncogene. 1996;12:2631–40. 
71 
 
216. Solmi R, Lauriola M, Francesconi M, Martini D, Voltattorni M, Ceccarelli C et al. 
Displayed correlation between gene expression profiles and submicroscopic alterations in 
response to cetuximab, gefitinib and EGF in human colon cancer cell lines. BMC Cancer. 
2008 Aug 8;8:227. 
217. Goran Hamid Mohammad, S. W. M. Olde Damink, Massimo Malago, Dipok Kumar 
Dhar and Stephen P. Pereira Pyruvate Kinase M2 and Lactate Dehydrogenase A Are 
Overexpressed in Pancreatic Cancer and Correlate with Poor Outcome PLoS One. 2016; 
11(3): e0151635. Published online 2016 Mar 18. 
218. Bolzoni M, Chiu M, Accardi F, Vescovini R, Airoldi , Storti P et al.Dependence on 
glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive 
target. Blood. 2016 Aug 4;128(5):667-79. 
219. Isei Tanida, Takashi Ueno, Eiki Kominami LC3 and Autophagy Autophagosome and 
Phagosome Volume 445 of the series Methods in Molecular Biology™ pp 77-88 
220. Katayama K, Noguchi K, and Sugimoto Y Regulations of P-
Glycoprotein/ABCB1/MDR1 in Human Cancer Cells. New Journal of Science Volume 2014 
(2014), Article ID 476974 
221. Landreville S, Agapova OA, Kneass ZT, Salesse C, Harbour JW. ABCB1 identifies a 
subpopulation of uveal melanoma cells with high metastatic propensity. Pigment Cell 
Melanoma Res. 2011 Jun;24(3):430-7. 
222. Ramarao Malla,Sreelatha Gopinath,Kiranmai Alapati,Christopher S. Gondi, Meena 
Gujrati,Dzung H. Dinh,Sanjeeva Mohanam,Jasti S. RaoDownregulation of uPAR and 
Cathepsin B Induces Apoptosis via Regulation of Bcl-2 and Bax and Inhibition of the 
PI3K/Akt Pathway in Gliomas. Plos One October 29, 2010 
223. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, 
Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti 
F, Libra M, Milella M, Tafuri A, Bonati A, Bäsecke J, Cocco L, Evangelisti C, Martelli AM, 
Montalto G, Cervello M, McCubrey JA.Roles of the Raf/MEK/ERK and 
PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-
implications for cancer and aging. Aging (Albany NY). 2011 Mar;3(3):192-222. 
224. Diwakar R Pattabiraman and Robert A. Weinberg Tackling the cancer stem cells – 
what challenges do they pose? Nat Rev Drug Discov. 2014 Jul; 13(7): 497–512. 
225. Ghiaur G, Gerber J, Jones RJ. Concise review: Cancer stem cells and minimal 
residual disease. Stem Cells. 2012 Jan;30(1) 
72 
 
226. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors.Cell. 2006 Aug 25;126(4):663-
76. Epub 2006 Aug 10. 
227. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, Maruyama M, 
Maeda M, Yamanaka S.The homeoprotein Nanog is required for maintenance of 
pluripotency in mouse epiblast and ES cells.Cell. 2003 May 30;113(5):631-42. 
228. Guilai Shi and Ying Jin. Role of Oct4 in maintaining and regaining stem cell 
pluripotency. Stem Cell Research & Therapy20101:39 
229. Kyung Hee Noh, Bo Wook Kim, Kwon-Ho Song, Hanbyoul Cho, Young-Ho Lee, Jin 
Hee Kim, Joon-Yong Chung, Jae-Hoon Kim, Stephen M. Hewitt, Seung-Yong Seong,Chih-
Ping Mao, T.-C. Wu and Tae Woo Kim. Nanog signaling in cancer promotes stem-like 
phenotype and immune evasion. J Clin Invest. 2012 Nov 1; 122(11): 4077–4093. 
230. Weiren Luo, Siyi Li, Bailu Peng, Yanfen Ye, Xubin Deng and Kaitai Yao. Embryonic 
Stem Cells Markers SOX2, OCT4 and Nanog Expression and Their Correlations with 
Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma. PLoS One. 2013; 8(2): 
e56324.  
231. Del Rosso M, Fibbi G, Pucci M, D’Alessio S, Del Rosso A, Magnelli L, Chiarugi V 
Multiple pathways of cell invasion are regulated by multiple families of serine proteases. 
Clin Exp Metastasis 19:193–207PubMedCrossRefGoogle Scholar 
232. Fibbi G, Caldini R, Chevanne M, Pucci M, Schiavone N, Morbidelli L, Parenti A, 
Granger HJ, Del Rosso M, Ziche M Urokinase-dependent angiogenesis in vitro and 
diacylglycerol production are blocked by antisense oligonucleotides against the urokinase 
receptor. Lab Invest 78:1109-1119 
233. Fibbi G, Ziche M, Morbidelli L, Magnelli L, Del Rosso M Interaction of urokinase 
with specific receptors stimulates mobilization of bovine adrenal capillary endothelial 
cells. Exp Cell Res 179:385–395 
234. D’Alessio S, Margheri F, Pucci M, Del Rosso A, Monia BP, Bologna M, Leonetti C, 
Scarsella M, Zupi G, Fibbi G et al Antisense oligodeoxynucleotides for urokinase-
plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro 
and inhibit spontaneous metastases of human melanoma in mice. Int J Cancer 
110(1):125–133 
235. Rao JS, Gondi C, Chetty C, Chittivelu S, Joseph PA, Lakka SS Inhibition of invasion, 
angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of 
73 
 
antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol Cancer Ther 4:1399–
1408 
236. Jo M, Lester RD, Montel V, Eastman B, Takimoto S, Gonias SL Reversibility of 
epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of 
urokinase receptor-dependent cell signaling. J Biol Chem 284:22825–22833 
237. Lester RD, Jo M, Montel V, Takimoto S, Gonias SL uPAR induces epithelial-
mesenchymal transition in hypoxic breast cancer cells. J Cell Biol 178:425–436 
238. Serratì S, Margheri F, Pucci M, Cantelmo AR, Cammarota R, Dotor J, Borràs-Cuesta 
F, Fibbi G, Albini A, Del Rosso M TGFbeta1 antagonistic peptides inhibit TGFbeta1-
dependent angiogenesis. Biochem Pharmacol 77:813–825 
239. Santibanez JF Transforming growth factor-Beta and urokinase-type plasminogen 
activator: dangerous partners in tumorigenesis-implications in skin cancer. Dermatol 
597927 
240. Margheri F, Schiavone N, Papucci L, Magnelli L, Serratì S, Chillà A, Laurenzana A, 
Bianchini F, Calorini L, Torre E et al (2012) GDF5 regulates TGFß-dependent angiogenesis 
in breast carcinoma MCF-7 cells: in vitro and in vivo control by anti-TGFß peptides. PLoS 
One 7:e50342 
241. Ulisse S, Baldini E, Sorrenti S, D'Armiento M. The urokinase plasminogen activator 
system: a target for anti-cancer therapy. Current cancer drug targets. 2009;9:32–71. 
242. Boonstra MC, Verspaget HW, Ganesh S, Kubben FJ, Vahrmeijer AL, van de Velde 
CJ, Kuppen PJ, Quax PH, Sier CF. Clinical applications of the urokinase receptor (uPAR) for 
cancer patients. Current pharmaceutical design. 2011;17:1890–1910 
243. Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional 
therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 
2009;106:13820–13825. 
244. Tehranchi R, Woll PS, Anderson K, et al. Persistent malignant stem cells in del(5q) 
myelodysplasia in remission. N Engl J Med. 2010;363:1025–1037. 
245. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human 
brain tumors. Cancer Res. 2003;63:5821–5828. 
246. Nordling CO. A new theory on cancer-inducing mechanism. Br J Cancer. 
1953;7:68–72. 
247. Ashley DJ. The two “hit” and multiple “hit” theories of carcinogenesis. Br J Cancer. 
1969;23:313–328. 
74 
 
248. Knudson AG., Jr Mutation, cancer: Statistical study of retinoblastoma. Proc Natl 
Acad Sci USA. 1971;68:820–823. 
249. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194:23–
28. 
250. Mazzieri R, Masiero L, Zanetta L et al. Control of type IV collagenase activity by 
components of the urokinase-plasmin system: a regulatory mechanism with cell-bound 
reactants. EMBO J 1997; 16(9): 2319–32. 
251. Ferrara N. Role of vascular endothelial growth factor in the regulation of 
angiogenesis. Kidney Int 1999; 56: 794–814 
252. Nathan Moore and Stephen Lyle. Quiescent, Slow-Cycling Stem Cell Populations 
in Cancer: A Review of the Evidence and Discussion of SignificanceHindawi Publishing 
Corporation Journal of Oncology Volume 2011, Article ID 396076, 11 
253. Anjomshoaa A, et al. Slow proliferation as a biological feature of colorectal cancer 
metastasis. Br J Cancer. 2009;101:822–828. 
254. Roesch A, et al. A temporarily distinct subpopulation of slow-cycling melanoma 
cells is required for continuous tumor growth. Cell. 2010;141:583–594. 
255. Pece S, et al. Biological and molecular heterogeneity of breast cancers correlates 
with their cancer stem cell content. Cell. 2010;140:62–73. 
256. Gupta PB, et al. Identification of selective inhibitors of cancer stem cells by high-
throughput screening. Cell. 2009;138:645–659. 
257. Kurrey NK, et al. Snail and slug mediate radioresistance and chemoresistance by 
antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian 
cancer cells. Stem Cells. 2009;27:2059–2068. 
258. Feuerhake F, Sigg W, Hofter EA, Dimpfl T, Welsch U. Immunohistochemical 
analysis of Bcl-2 and Bax expression in relation to cell turnover and epithelial 
differentiation markers in the non-lactating human mammary gland epithelium. Cell 
Tissue Res. 2000;299:47–58. 
259. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional 
properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 
1996;183:1797–1806. 
260. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-
like cells in the C6 glioma cell line. Proc Natl Acad Sci U S A. 2004;101:781–786. 
75 
 
261. Zhou S, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of 
stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 
2001;7:1028–1034. 
262. Ricardo Pardal, Michael F. Clarke & Sean J. Morrison Applying the principles of 
stem-cell biology to cancer. Nature Reviews Cancer 3, 895-902 (December 2003) 
263. Gondi CS, Kandhukuri N, Kondraganti S, Gujrati M, Olivero WC, et al. (2006) RNA 
interference-mediated simultaneous down-regulation of urokinase-type plasminogen 
activator receptor and cathepsin B induces caspase-8-mediated apoptosis in SNB19 
human glioma cells. Mol Cancer Ther 5: 3197–3208. 
264. Kin Y, Chintala SK, Go Y, Sawaya R, Mohanam S, et al. (2000) A novel role for the 
urokinase-type plasminogen activator receptor in apoptosis of malignant gliomas. Int J 
Oncol 17: 61–65. 
265. Warburg O, Wind F, Negelein E. The Metabolism of Tumors in the Body. J Gen 
Physiol. 1927;8:519–530. 
266. Dong C, et al. Loss of FBP1 by Snail-mediated repression provides metabolic 
advantages in basal-like breast cancer. Cancer Cell. 2013;23:316–331. 
267. Ginestier C, et al. Mevalonate metabolism regulates Basal breast cancer stem cells 
and is a potential therapeutic target. Stem Cells. 2012;30:1327–1337. 
268. Fantin VR, St-Pierre J, Leder P. 2006. Attenuation of LDH-Aexpression uncovers a 
link between glycolysis, mitochondrialphysiology, and tumor maintenance. Cancer Cell 9: 
425–434. 
269. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM,Royer RE, Vander Jagt 
DL, Semenza GL, Dang CV. 2010.Inhibition of lactate dehydrogenase A induces oxidative 
stressand inhibits tumor progression. Proc Natl Acad Sci 107:2037–2042 
270. Warburg O. 1956. On respiratory impairment in cancer cells. Science 124: 269 
271. Vander Heiden MG, Cantley LC, Thompson CB. 2009. Understandingthe Warburg 
effect: The metabolic requirements of cell proliferation. Science 324: 1029–1033. 
272. Gillies RJ, Robey I, Gatenby RA. 2008. Causes and consequencesof increased 
glucose metabolism of cancers. J Nucl Med 49(Suppl 2): 24S–42S. 
273. Warburg O. 1956. On the origin of cancer cells. Science 123:309–314. 
274. Gatenby RA, Gillies RJ. 2004. Why do cancers have high aerobicglycolysis? Nat Rev 
Cancer 4: 891–899. 
76 
 
275. Peppicelli S, Bianchini F, Calorini L. Extracellular acidity, a "reappreciated" trait of 
tumor environment driving malignancy: perspectives in diagnosis and therapy.Cancer 
Metastasis Rev. 2014 Sep;33(2-3):823-32. 
276. Peppicelli S, Bianchini F, Torre E, Calorini L. Contribution of acidic melanoma cells 
undergoing epithelial-to-mesenchymal transition to aggressiveness of non-acidic 
melanoma cells.Clin Exp Metastasis. 2014 Apr;31(4):423-33. doi: 10.1007/s10585-014-
9637-6. Epub 2014 Jan 28. 
277. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A,Gerszten RE,Wei R, 
Fleming MD, Schreiber SL, Cantley LC.2008a. The M2 splice isoform of pyruvate kinase is 
important for cancer metabolism and tumour growth. Nature 452:230–233. 
278. Christofk HR, Vander Heiden MG, Wu N, Asara JM, CantleyLC. 2008b. Pyruvate 
kinase M2 is a phosphotyrosine-bindingprotein. Nature 452: 181–186. 
279. Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H,Heffron GJ, Amador-
Noguez D, Christofk HR, Wagner G,Rabinowitz JD, Asara JM, et al. 2010. Evidence for an 
alternativeglycolytic pathway in rapidly proliferating cells. Science329: 1492–1499. 
280. Kuo W, Lin J, Tang TK.Human glucose-6-phosphate dehydrogenase (G6PD) gene 
transforms NIH 3T3 cells and induces tumors in nude mice.Int J Cancer. 2000 Mar 
15;85(6):857-64. 
281. Vaughn AE, Deshmukh M. 2008. Glucose metabolism inhibitsapoptosis in neurons 
and cancer cells by redox inactivation of cytochrome c. Nat Cell Biol 10: 1477–1483. 
282. Alpízar-Alpízar W, Christensen IJ, Santoni-Rugiu E, Skarstein A, Ovrebo K, Illemann 
M, Laerum OD.Urokinase plasminogen activator receptor on invasive cancer cells: a 
prognostic factor in distal gastric adenocarcinoma.Int J Cancer. 2012 Aug 15;131(4):E329-
36. Epub 2011 Oct 20. 
283. Patrick M. Brunner, Patricia C. Heier, Judit Mihaly-Bison, Ute Priglinger, Bernd R. 
Binder and Gerald W. Prager. Density enhanced phosphatase-1 down-regulates urokinase 
receptor surface expression in confluent endothelial cells. Blood 2011 117:4154-4161 
284. Rosemary Bass, Vincent Ellis. Regulation of urokinase receptor function and 
pericellular proteolysis by the integrin α5β1Thrombosis and Haemostasis, 101 (5). pp. 
954-962. 
285. Simon DI, Wei Y, Zhang L, Rao NK, Xu H, Chen Z, Liu Q, Rosenberg S, Chapman 
HA.Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator 
of integrin function.J Biol Chem. 2000 Apr 7;275(14):10228-34. 
77 
 
286. Ying Wei, Johannes A. Eble, Zemin Wang, Jordan A. Kreidberg, and Harold A. 
Chapman. Urokinase Receptors Promote β1 Integrin Function through Interactions with 
Integrin α3β1. Mol Biol Cell. 2001 Oct; 12(10): 2975–2986. 
